<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2908</journal-id><journal-id journal-id-type="pmc-domain">antibiot</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11428266</article-id><article-id pub-id-type="pmcid-ver">PMC11428266.1</article-id><article-id pub-id-type="pmcaid">11428266</article-id><article-id pub-id-type="pmcaiid">11428266</article-id><article-id pub-id-type="pmid">39334976</article-id><article-id pub-id-type="doi">10.3390/antibiotics13090801</article-id><article-id pub-id-type="publisher-id">antibiotics-13-00801</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Risk Factors Associated with Antibiotic Exposure Variability in Critically Ill Patients: A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3941-2569</contrib-id><name name-style="western"><surname>Gras-Mart&#237;n</surname><given-names initials="L">Laura</given-names></name><xref rid="af1-antibiotics-13-00801" ref-type="aff">1</xref><xref rid="af2-antibiotics-13-00801" ref-type="aff">2</xref><xref rid="af3-antibiotics-13-00801" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Plaza-Diaz</surname><given-names initials="A">Adri&#225;n</given-names></name><xref rid="af1-antibiotics-13-00801" ref-type="aff">1</xref><xref rid="af2-antibiotics-13-00801" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zarate-Tamames</surname><given-names initials="B">Borja</given-names></name><xref rid="af1-antibiotics-13-00801" ref-type="aff">1</xref><xref rid="af2-antibiotics-13-00801" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3346-5093</contrib-id><name name-style="western"><surname>Vera-Artazcoz</surname><given-names initials="P">Paula</given-names></name><xref rid="af2-antibiotics-13-00801" ref-type="aff">2</xref><xref rid="af3-antibiotics-13-00801" ref-type="aff">3</xref><xref rid="af4-antibiotics-13-00801" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0305-8211</contrib-id><name name-style="western"><surname>Torres</surname><given-names initials="OH">Olga H.</given-names></name><xref rid="af2-antibiotics-13-00801" ref-type="aff">2</xref><xref rid="af3-antibiotics-13-00801" ref-type="aff">3</xref><xref rid="af5-antibiotics-13-00801" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0845-8107</contrib-id><name name-style="western"><surname>Bastida</surname><given-names initials="C">Carla</given-names></name><xref rid="af6-antibiotics-13-00801" ref-type="aff">6</xref><xref rid="af7-antibiotics-13-00801" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8128-345X</contrib-id><name name-style="western"><surname>Soy</surname><given-names initials="D">Dolors</given-names></name><xref rid="af6-antibiotics-13-00801" ref-type="aff">6</xref><xref rid="af7-antibiotics-13-00801" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0008-641X</contrib-id><name name-style="western"><surname>Ruiz-Ramos</surname><given-names initials="J">Jes&#250;s</given-names></name><xref rid="af1-antibiotics-13-00801" ref-type="aff">1</xref><xref rid="af2-antibiotics-13-00801" ref-type="aff">2</xref><xref rid="af3-antibiotics-13-00801" ref-type="aff">3</xref><xref rid="c1-antibiotics-13-00801" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Lipman</surname><given-names initials="J">Jeffrey</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antibiotics-13-00801"><label>1</label>Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain; <email>lgras@santpau.cat</email> (L.G.-M.); <email>aplaza@santpau.cat</email> (A.P.-D.); <email>bzarate@santpau.cat</email> (B.Z.-T.)</aff><aff id="af2-antibiotics-13-00801"><label>2</label>Institut de Recerca Sant Pau (IR SANT PAU), Sat Quint&#237; 77-79, 08041 Barcelona, Spain; <email>pvera@santpau.cat</email> (P.V.-A.); or <email>otorres@santpau.cat</email> (O.H.T.)</aff><aff id="af3-antibiotics-13-00801"><label>3</label>Department of Medicine, Universitat Aut&#242;noma de Barcelona, 08193 Bellaterra, Spain</aff><aff id="af4-antibiotics-13-00801"><label>4</label>Intensive Care Department, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain</aff><aff id="af5-antibiotics-13-00801"><label>5</label>Geriatric Unit, Internal Medicine Department, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain</aff><aff id="af6-antibiotics-13-00801"><label>6</label>Pharmacy Department, Division of Medicines, Hospital Clinic of Barcelona, Villarroel 170, 08036 Barcelona, Spain; <email>cbastida@clinic.cat</email> (C.B.); </aff><aff id="af7-antibiotics-13-00801"><label>7</label>Department of Pharmacology, Toxicology and Therapeutical Chemistry, Faculty of Pharmacy, Universitat de Barcelona, Campus Diagonal, Av. de Joan XXIII, 27-31, 08028 Barcelona, Spain</aff><author-notes><corresp id="c1-antibiotics-13-00801"><label>*</label>Correspondence: <email>jrzrms@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>13</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">471573</issue-id><elocation-id>801</elocation-id><history><date date-type="received"><day>19</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-29 15:25:18.037"><day>29</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="antibiotics-13-00801.pdf"/><abstract><p>(1) Background: Knowledge about the behavior of antibiotics in critically ill patients has been increasing in recent years. Some studies have concluded that a high percentage may be outside the therapeutic range. The most likely cause of this is the pharmacokinetic variability of critically ill patients, but it is not clear which factors have the greatest impact. The aim of this systematic review is to identify risk factors among critically ill patients that may exhibit significant pharmacokinetic alterations, compromising treatment efficacy and safety. (2) Methods: The search included the PubMed, Web of Science, and Embase databases. (3) Results: We identified 246 observational studies and ten clinical trials. The most studied risk factors in the literature were renal function, weight, age, sex, and renal replacement therapy. Risk factors with the greatest impact included renal function, weight, renal replacement therapy, age, protein or albumin levels, and APACHE or SAPS scores. (4) Conclusions: The review allows us to identify which critically ill patients are at a higher risk of not reaching therapeutic targets and helps us to recognize the extensive number of risk factors that have been studied, guiding their inclusion in future studies. It is essential to continue researching, especially in real clinical practice and with clinical outcomes.</p></abstract><kwd-group><kwd>pharmacokinetics</kwd><kwd>pharmacodynamics</kwd><kwd>critically ill patients</kwd><kwd>antibiotic</kwd><kwd>exposure</kwd><kwd>target attainment</kwd><kwd>risk factors</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-13-00801"><title>1. Introduction</title><p>Sepsis is a life-threatening organ dysfunction, impacting millions of people around the world each year and killing one in three to one in six of those it affects. Early administration of appropriate antimicrobial treatment is one of the most effective interventions to reduce mortality in patients with sepsis. Therefore, it is essential to carry out effective and safe anti-infective treatment [<xref rid="B1-antibiotics-13-00801" ref-type="bibr">1</xref>].</p><p>Knowing the optimal dosage of these drugs is very complex because, unlike other treatments, the pharmacological effect cannot be evaluated immediately. It is known that the behavior of drugs depends on the relationship between their pharmacokinetics and pharmacodynamics (PK/PD). In the case of antimicrobial agents, pharmacodynamics refers to the minimum inhibitory concentration (MIC) of the microorganism to be treated. This relationship has been extensively studied in recent years, especially in critically ill patients [<xref rid="B2-antibiotics-13-00801" ref-type="bibr">2</xref>,<xref rid="B3-antibiotics-13-00801" ref-type="bibr">3</xref>,<xref rid="B4-antibiotics-13-00801" ref-type="bibr">4</xref>,<xref rid="B5-antibiotics-13-00801" ref-type="bibr">5</xref>,<xref rid="B6-antibiotics-13-00801" ref-type="bibr">6</xref>,<xref rid="B7-antibiotics-13-00801" ref-type="bibr">7</xref>]. This knowledge, along with the increase in resistance, has led to the discovery that the initially assumed PK/PD targets are not sufficient to resolve the infection. Studies conducted on the PK/PD of antibiotics in critically ill patients have made it possible to define specific therapeutic targets for these patients [<xref rid="B8-antibiotics-13-00801" ref-type="bibr">8</xref>,<xref rid="B9-antibiotics-13-00801" ref-type="bibr">9</xref>,<xref rid="B10-antibiotics-13-00801" ref-type="bibr">10</xref>,<xref rid="B11-antibiotics-13-00801" ref-type="bibr">11</xref>,<xref rid="B12-antibiotics-13-00801" ref-type="bibr">12</xref>,<xref rid="B13-antibiotics-13-00801" ref-type="bibr">13</xref>,<xref rid="B14-antibiotics-13-00801" ref-type="bibr">14</xref>].</p><p>The pharmacokinetics of the anti-infective agents are crucial for attaining their optimal effect, and we know that they are highly variable in critically ill patients [<xref rid="B15-antibiotics-13-00801" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-13-00801" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-13-00801" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-13-00801" ref-type="bibr">18</xref>,<xref rid="B19-antibiotics-13-00801" ref-type="bibr">19</xref>,<xref rid="B20-antibiotics-13-00801" ref-type="bibr">20</xref>,<xref rid="B21-antibiotics-13-00801" ref-type="bibr">21</xref>]. When a patient is admitted to the intensive care unit (ICU), significant physiological changes occur that are generally not considered in the design of dosing regimens. The factors influencing changes in pharmacokinetics vary across different sources, and there is a lack of consistent data on the true impact and magnitude of each factor. Some of these factors include renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), obesity, aging, or comorbidities, which are also increasing in these units [<xref rid="B22-antibiotics-13-00801" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-13-00801" ref-type="bibr">23</xref>,<xref rid="B24-antibiotics-13-00801" ref-type="bibr">24</xref>,<xref rid="B25-antibiotics-13-00801" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-13-00801" ref-type="bibr">26</xref>,<xref rid="B27-antibiotics-13-00801" ref-type="bibr">27</xref>,<xref rid="B28-antibiotics-13-00801" ref-type="bibr">28</xref>,<xref rid="B29-antibiotics-13-00801" ref-type="bibr">29</xref>,<xref rid="B30-antibiotics-13-00801" ref-type="bibr">30</xref>,<xref rid="B31-antibiotics-13-00801" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-13-00801" ref-type="bibr">32</xref>]. In fact, several studies have concluded that high percentages of critically ill patients on antibiotic treatment have plasma concentrations outside the therapeutic range, including several groups of antibiotics [<xref rid="B33-antibiotics-13-00801" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-13-00801" ref-type="bibr">34</xref>,<xref rid="B35-antibiotics-13-00801" ref-type="bibr">35</xref>,<xref rid="B36-antibiotics-13-00801" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-13-00801" ref-type="bibr">37</xref>,<xref rid="B38-antibiotics-13-00801" ref-type="bibr">38</xref>]. </p><p>Despite this information, standard doses are still frequently used for these patients, with little consensus on the appropriate dosing [<xref rid="B39-antibiotics-13-00801" ref-type="bibr">39</xref>,<xref rid="B40-antibiotics-13-00801" ref-type="bibr">40</xref>]. The only way to ensure that patients achieve adequate antibiotic exposure and thus avoid therapeutic failures and side effects is through the determination of plasma concentration. However, this practice is not available for all patients in most centers due to costs and lack of evidence on clinical outcomes [<xref rid="B10-antibiotics-13-00801" ref-type="bibr">10</xref>,<xref rid="B41-antibiotics-13-00801" ref-type="bibr">41</xref>,<xref rid="B42-antibiotics-13-00801" ref-type="bibr">42</xref>,<xref rid="B43-antibiotics-13-00801" ref-type="bibr">43</xref>,<xref rid="B44-antibiotics-13-00801" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-13-00801" ref-type="bibr">45</xref>,<xref rid="B46-antibiotics-13-00801" ref-type="bibr">46</xref>,<xref rid="B47-antibiotics-13-00801" ref-type="bibr">47</xref>,<xref rid="B48-antibiotics-13-00801" ref-type="bibr">48</xref>,<xref rid="B49-antibiotics-13-00801" ref-type="bibr">49</xref>,<xref rid="B50-antibiotics-13-00801" ref-type="bibr">50</xref>,<xref rid="B51-antibiotics-13-00801" ref-type="bibr">51</xref>,<xref rid="B52-antibiotics-13-00801" ref-type="bibr">52</xref>,<xref rid="B53-antibiotics-13-00801" ref-type="bibr">53</xref>]. Most of these studies exhibit considerable variability in terms of the drugs studied, infections, causative microorganisms, and patient characteristics. In ICUs, we find very heterogeneous patients, and it is likely that pharmacokinetic variability will not be the same in all of them, nor will the impact on dosing, antibiotic exposure, and clinical outcomes.</p><p>The aim of this systematic review is to identify risk factors in critically ill patients who may present relevant pharmacokinetic alterations that compromise the efficacy and safety of the treatment.</p></sec><sec sec-type="results" id="sec2-antibiotics-13-00801"><title>2. Results</title><p>A total of 4895 articles were identified through computer searches in the selected databases, with 1141 duplicates removed through electronic or manual methods. A total of 3754 studies were screened by title and abstract and 489 were assessed for eligibility by full-text assessment. A total of 256 studies were finally included in the systematic review (<xref rid="antibiotics-13-00801-f001" ref-type="fig">Figure 1</xref>). Detailed reporting quality and risk-of-bias assessments are presented in <xref rid="app1-antibiotics-13-00801" ref-type="app">Figures S1 and S2</xref> (<xref rid="app1-antibiotics-13-00801" ref-type="app">Supplementary Materials; File S3</xref>).</p><p>Most of the studies found were prospective, observational, and single-center studies. Different types of studies could be distinguished based on whether the outcome was to evaluate pharmacokinetic variability (evaluate alterations in the clearance and/or volume of distribution), develop a population pharmacokinetic model (PKPOP) (develop pharmacokinetic models tailored to critically ill patients using specialized software such as Nonmem<sup>&#174;</sup>), or assess antibiotic exposure variability (evaluate variations in antimicrobial concentrations without assessing pharmacokinetic parameters). Only nine studies (3.50%) also evaluated clinical outcomes. The average number of patients per study was 85.3, ranging from three to 7220 patients. These studies were conducted practically worldwide, although the numbers varied widely by region. They included studies on many different antibiotics, with studies on beta-lactams being prominent (n = 136), followed by vancomycin (n = 42). The remaining characteristics of the analyzed studies are presented in <xref rid="antibiotics-13-00801-t001" ref-type="table">Table 1</xref>.</p><p>The most studied risk factors in the publications were renal function, weight, age, sex, and renal replacement. The risk factors that were found to have the most impact were renal function, weight, renal replacement, age, and protein or albumin levels, in that order. Looking at the risk factors by the percentage of studies that concluded differences versus the studies analyzed, the risk factors with the most impact were renal function, burns, acid&#8211;base parameters, trauma, and renal replacement. The risk factors studied in each study, the number of articles that analyzed them, and the number of articles that established them as determinants, classified by antibiotic group and for each outcome type (pharmacokinetic parameters or population model and exposure), are included in <xref rid="antibiotics-13-00801-t002" ref-type="table">Table 2</xref>. The percentage of risk factors that had the greatest influence, represented by drug group, and the effect of each risk factor by drug group can be observed in <xref rid="antibiotics-13-00801-f002" ref-type="fig">Figure 2</xref>. Some studies do not conclude statistically significant differences but do determine that there is considerable variability. </p><p>Some of the risk factors include different characteristics. Sepsis or septic shock was assessed based on the presence of these conditions, the use of vasopressors, or mean arterial pressure, while acute phase reactants were evaluated using C-reactive protein, fever, procalcitonin, or leukocyte count. Leukocyte count was the only factor among them that was not found to be relevant in any study. From studies concluding that blood protein levels were relevant, 86.67% included only albumin. Diabetes mellitus, congestive heart failure, cancer, chronic obstructive pulmonary disease (COPD), and neutropenia were the relevant associated comorbidities, all for beta-lactams except COPD, which was associated with vancomycin. The only two diagnoses associated with different outcomes were acute respiratory distress syndrome in one study and neurocritical in another. Midazolam was the determining comedication for daptomycin, and drug interactions with quinolones were significant. Types of infections showing differences were abdominal focus sepsis for aminoglycosides and beta-lactams, the Pitt bacteremia score for beta-lactams, and respiratory infections for linezolid and beta-lactams (one study for each). The details of the relevant risk factors that include more different variables can be seen in <xref rid="antibiotics-13-00801-f002" ref-type="fig">Figure 2</xref> and <xref rid="antibiotics-13-00801-f003" ref-type="fig">Figure 3</xref>.</p><p>Other risk factors associated with inadequate exposure (evaluated in only one study) were lower protein binding beta-lactams, CYP1A2 polymorphism for ciprofloxacin, heart failure, McCabe score, infusion duration, and high drainage fluid production for beta-lactams. There were also other risk factors related to relevant pharmacokinetic changes: serum sodium, brain glucose concentration, uric acid, cardiac index, and ICU-onset infection. The review identified several other variables that, despite being analyzed, did not significantly impact achieving adequate antimicrobial concentrations or the pharmacokinetic models developed. A comprehensive list of these variables is available in the <xref rid="app1-antibiotics-13-00801" ref-type="app">Supplementary Materials (File S4)</xref>.</p><p>Some risk factors have been studied much more extensively than others. The relationship between the number of publications that analyzed a risk factor (and the number of patients) versus the number of publications that concluded that risk factors were determinants can be observed in <xref rid="antibiotics-13-00801-f004" ref-type="fig">Figure 4</xref>.</p></sec><sec sec-type="discussion" id="sec3-antibiotics-13-00801"><title>3. Discussion</title><p>To the best of our knowledge, this is the first systematic review to identify risk factors in critically ill patients that may compromise the efficacy and safety of antibiotic treatments which included more than just population kinetics. Recently, a very comprehensive systematic review was published, but it included only studies developing population kinetics and focused solely on beta-lactams [<xref rid="B54-antibiotics-13-00801" ref-type="bibr">54</xref>]. Population kinetics can be very helpful in determining the variability of exposure to a treatment, but what we are really interested in is whether these changes will have a clinical impact. Unfortunately, we found very few studies that directly link risk factors to antimicrobial underexposure and clinical outcomes. However, considering the strong correlation between appropriate antibiotic exposure and clinical outcomes [<xref rid="B55-antibiotics-13-00801" ref-type="bibr">55</xref>], analyzing clinical and demographic variables that might influence antibiotic exposure is highly relevant. Various scientific societies and international consensus groups have emphasized the importance of PK/PD objectives in improving clinical outcomes for critically ill patients [<xref rid="B10-antibiotics-13-00801" ref-type="bibr">10</xref>]. Currently, we have information about the desired therapeutic targets, and these have indeed been directly related to significant clinical variables [<xref rid="B8-antibiotics-13-00801" ref-type="bibr">8</xref>,<xref rid="B9-antibiotics-13-00801" ref-type="bibr">9</xref>,<xref rid="B10-antibiotics-13-00801" ref-type="bibr">10</xref>,<xref rid="B11-antibiotics-13-00801" ref-type="bibr">11</xref>,<xref rid="B12-antibiotics-13-00801" ref-type="bibr">12</xref>,<xref rid="B13-antibiotics-13-00801" ref-type="bibr">13</xref>,<xref rid="B14-antibiotics-13-00801" ref-type="bibr">14</xref>]. Including other antibiotics has also helped identify risk factors that may be relevant to therapeutic groups other than beta-lactams, such as liver function in the case of linezolid.</p><p>Numerous narrative reviews have explored optimizing antimicrobial dosing in critically ill patients, emphasizing strategies such as extended infusions and higher dosages based on variations in drug clearance and volume of distribution [<xref rid="B2-antibiotics-13-00801" ref-type="bibr">2</xref>,<xref rid="B5-antibiotics-13-00801" ref-type="bibr">5</xref>]. Our review seeks to advance this discussion by identifying less commonly considered parameters that may also influence antimicrobial concentrations in this patient group. We analyzed all the risk factors examined in the studies and highlighted the most significant ones. Our approach not only considers the number of studies that reviewed each factor but also the percentage of studies that found each factor relevant. This method helps us discern which factors have been extensively studied and which have not, particularly when statistical significance is challenging to achieve due to the limited number of studies or small patient populations.</p><p>While previous reviews on pharmacokinetics in critically ill patients have predominantly addressed differences from a theoretical perspective&#8212;focusing on variations in the volume of distribution, renal function, antimicrobial penetration challenges, and the lipophilicity of these drugs [<xref rid="B56-antibiotics-13-00801" ref-type="bibr">56</xref>], our review takes a more practical approach. We evaluate multiple pharmacokinetic models specifically developed for critically ill patients, allowing us to group and quantify the significance of several less commonly discussed variables in antimicrobial pharmacokinetics.</p><p>We concur with the recently published population pharmacokinetics review of beta-lactams [<xref rid="B54-antibiotics-13-00801" ref-type="bibr">54</xref>] that renal function, weight, and renal replacement have the greatest impact on antibiotic exposure, in that order. While it seems clear that these three risk factors affect antibiotic exposure in critically ill patients, dosing regimens used in these settings for most antibiotics are not weight-adjusted. With the increasing prevalence of obesity in both the general population and among patients in critical care units, weight and body surface area have become increasingly important factors in justifying antimicrobial monitoring in critically ill patients. Critically ill obese patients may require higher-than-standard doses of &#946;-lactams, linezolid, and quinolones [<xref rid="B57-antibiotics-13-00801" ref-type="bibr">57</xref>]. Conversely, dosing should be based on total body weight for certain antibiotics such as amikacin, vancomycin, or daptomycin, while adjusted body weight should be used for others. Given the limited availability of pharmacokinetic studies in this patient population and the significant variability in pharmacokinetics among critically ill patients, therapeutic drug monitoring of all administered antibiotics, when possible, is highly recommended.</p><p>Regarding beta-lactam drugs, the therapeutic group most commonly used in critically ill patients, our review identified multiple variables associated with variations in plasma concentrations, with weight, renal function, renal replacement therapy (RRT), and age being the most significant. The DALI study [<xref rid="B38-antibiotics-13-00801" ref-type="bibr">38</xref>] revealed that with the doses typically used, about 26% of patients did not reach the minimum target concentration of fT &gt; 50%, and nearly 40% of patients did not achieve fT &gt; 100%. This study also correlated these variables with the clinical outcomes of the patients, highlighting the importance of considering different patient covariates to achieve adequate plasma concentrations. In a narrative review, Sta&#353;ek J et al. [<xref rid="B12-antibiotics-13-00801" ref-type="bibr">12</xref>] explained the main factors associated with variations in beta-lactam antibiotics in critically ill patients, focusing on renal function, inflammation, hypoalbuminemia, and renal replacement therapy. Our study complements the information provided by other authors, adding data to the number of patients and published articles that consider each variable and introducing new variables such as sex, acid&#8211;base disorders, diagnosis at admission, and the site of infections.</p><p>The information obtained on vancomycin was the second most abundant in terms of the number of studies, following beta-lactams. Compared to previous reviews [<xref rid="B58-antibiotics-13-00801" ref-type="bibr">58</xref>], which primarily focused on age, weight, and renal function, our study has identified additional variables, such as severity scales, trauma diagnosis on admission, and hypoalbuminemia, as potential factors to consider for optimizing the dose of this drug.</p><p>Although there are recommendations for different renal functions and RRT for most antibiotics, the literature often lacks consensus on the most appropriate doses. Additionally, crucial characteristics such as the type and dosage of RRT, which have been shown to be relevant in several studies, are often not considered. The other risk factors described as most relevant in the beta-lactam review and in our work are also similar. Some of these include age, serum albumin, and disease severity, and in no case is dose adjustment considered for these patients.</p><p>Both this work and the analyzed studies have limitations. The recommended methodology has been used, and the articles and the document with all the data have been reviewed by several people, but even so, the entire process remains very manual. As a result, we found significant heterogeneity in published population pharmacokinetic studies, which limited the feasibility of meaningfully pooling quantitative parameters. Critically ill patients is a term that includes a clinical heterogeneity of situations across eligible studies that enrolled different populations. We included studies that involved critically ill patients who underwent antimicrobial drug monitoring. However, it is unclear whether all patients had confirmed infections or were necessarily septic. The inclusion of patients who were not septic would increase the likelihood of finding no variables associated with subtherapeutic antibiotic concentrations. Additionally, although we have analyzed studies of all antibiotics without exclusion, a large number of studies are on beta-lactams. Moreover, beta-lactams are a very heterogeneous group of antibiotics, and it would be more appropriate to assess the risk factors affecting each of them separately. The studies that examine exposure do so at the described doses, which may differ from those used in each center. To be able to extrapolate the results from such a large number of articles, we had to combine studies that examine specific subgroups with studies that analyzed risk factors individually, which were not usually the main objective. Studies that reviewed risk factors as a secondary objective did not take this objective into account when calculating the sample size to determine statistical significance. We found that some risk factors are very under-studied, and some are studied in very few patients. There is a lack of studies in routine clinical practice that consider all associated factors and have a sufficient sample size to reach valuable conclusions. Based on the authors&#8217; linguistic expertise, only studies published in English and Spanish were included, which may have led to the exclusion of some studies that could have identified additional variables influencing the pharmacokinetics of antimicrobials in critically ill patients. However, the large number of studies incorporated ensures that the primary variables have been thoroughly considered.</p><p>Therefore, we align with the conclusions of many of the analyzed studies: variability in critically ill patients is very high, and the best way to ensure therapeutic target attainment in these patients is to perform Therapeutic Drug Monitoring (TDM). ICU patients are also highly variable among themselves, due to patient characteristics, the reason for admission, the need for vasoactive drugs or fluid replacement, comorbidities, concomitant treatments, lab abnormalities, or the need for extracorporeal supports, among other factors. The effect of the analyzed risk factors can be crucial in determining which patients, among the critically ill, may be at even greater risk of incorrect dosing, and this can be a criterion for prioritizing TDM if it cannot be performed in all patients.</p></sec><sec id="sec4-antibiotics-13-00801"><title>4. Materials and Methods</title><p>This systematic review was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO), identification code CRD42024570977. The protocol adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [<xref rid="B59-antibiotics-13-00801" ref-type="bibr">59</xref>]. </p><p>In order to achieve the objective of this systematic review and identify risk factors among critically ill patients, we conducted a search aimed at finding studies evaluating the effect of risk factors that could significantly influence antibiotic treatments in the ICU. </p><p>We searched for all published studies involving adult patients admitted to the ICU and receiving antibiotic treatment, investigating potential risk factors that could affect antibiotic exposure in these patients. Any variable examined in the included studies for its effect on plasma concentrations of antimicrobials was considered as a risk factor. The details of the search strategy can be found in the <xref rid="app1-antibiotics-13-00801" ref-type="app">Supplementary Materials</xref>.</p><p>All studies meeting these criteria were included, regardless of whether they focused on these factors as primary objectives or not, analyzed risk factors or directly assessed a population subgroup (e.g., obese patients, those undergoing continuous RRT, ECMO, etc.), studied antibiotic exposure (typically through plasma concentrations), or examined the impact on pharmacokinetic parameters. We categorized covariates using a preplanned, custom classification based on patterns commonly identified in a preliminary literature review conducted by the authors. Given the nature of this review, no formal sensitivity or subgroup analyses were prespecified to assess heterogenicity. Studies not in English or Spanish, retrospective studies, reviews, and abstracts were excluded. Other exclusion criteria were studies that did not assess pharmacokinetic variability or exposure, those that exclusively focused on non-antibiotic agents such as antivirals or antifungals, and those for which full-text access was unavailable.</p><p>The search was conducted on 21 March 2024 on the following bibliographic databases: PubMed, Web of Science, and Embase, according to the eligibility criteria and with no time restrictions. The data from searches in each database were exported to an Excel document, and an initial phase for the detection of duplicates was performed. A subsequent duplication detection phase was conducted in the resulting database using a DOI identifier and manual assessment. The results of the refined database were screened (title/abstract) by two independent investigators, with disagreements resolved by a third researcher. This method was replicated for the following full-text assessment and final inclusion of articles. Once selected, data were collected and validated by two independent investigators for each report. Finally, all data were processed in the Excel document, including the most important characteristics of each study.</p><p>We assessed the risk of bias in all included randomized clinical trials using Risk of Bias 2 (RoB2). Each study report was assessed by two authors independently, with any disagreements resolved by a third author. For clinical pharmacokinetics studies, the 24-item ClinPK checklist from the Reporting Guidelines for Clinical Pharmacokinetic Studies [<xref rid="B60-antibiotics-13-00801" ref-type="bibr">60</xref>] was used to evaluate the quality of the manuscripts.</p></sec><sec sec-type="conclusions" id="sec5-antibiotics-13-00801"><title>5. Conclusions</title><p>This review allows us to identify which critically ill patients are at a higher risk of not reaching therapeutic targets. This review also helps us recognize the extensive number of variables that have been studied, guiding their inclusion in future studies. It is essential to continue researching, especially in real clinical practice and with clinical outcomes.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-antibiotics-13-00801"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/antibiotics13090801/s1">https://www.mdpi.com/article/10.3390/antibiotics13090801/s1</uri>, File S1: Search strategy; File S2: Excluded and Included studies; File S3: Risk of bias analysis; File S4: Risk factors that were studied without finding any impact; File S5: Main characteristics of studies. References [<xref rid="B28-antibiotics-13-00801" ref-type="bibr">28</xref>,<xref rid="B32-antibiotics-13-00801" ref-type="bibr">32</xref>,<xref rid="B33-antibiotics-13-00801" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-13-00801" ref-type="bibr">34</xref>,<xref rid="B36-antibiotics-13-00801" ref-type="bibr">36</xref>,<xref rid="B49-antibiotics-13-00801" ref-type="bibr">49</xref>,<xref rid="B61-antibiotics-13-00801" ref-type="bibr">61</xref>,<xref rid="B62-antibiotics-13-00801" ref-type="bibr">62</xref>,<xref rid="B63-antibiotics-13-00801" ref-type="bibr">63</xref>,<xref rid="B64-antibiotics-13-00801" ref-type="bibr">64</xref>,<xref rid="B65-antibiotics-13-00801" ref-type="bibr">65</xref>,<xref rid="B66-antibiotics-13-00801" ref-type="bibr">66</xref>,<xref rid="B67-antibiotics-13-00801" ref-type="bibr">67</xref>,<xref rid="B68-antibiotics-13-00801" ref-type="bibr">68</xref>,<xref rid="B69-antibiotics-13-00801" ref-type="bibr">69</xref>,<xref rid="B70-antibiotics-13-00801" ref-type="bibr">70</xref>,<xref rid="B71-antibiotics-13-00801" ref-type="bibr">71</xref>,<xref rid="B72-antibiotics-13-00801" ref-type="bibr">72</xref>,<xref rid="B73-antibiotics-13-00801" ref-type="bibr">73</xref>,<xref rid="B74-antibiotics-13-00801" ref-type="bibr">74</xref>,<xref rid="B75-antibiotics-13-00801" ref-type="bibr">75</xref>,<xref rid="B76-antibiotics-13-00801" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-13-00801" ref-type="bibr">77</xref>,<xref rid="B78-antibiotics-13-00801" ref-type="bibr">78</xref>,<xref rid="B79-antibiotics-13-00801" ref-type="bibr">79</xref>,<xref rid="B80-antibiotics-13-00801" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-13-00801" ref-type="bibr">81</xref>,<xref rid="B82-antibiotics-13-00801" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-13-00801" ref-type="bibr">83</xref>,<xref rid="B84-antibiotics-13-00801" ref-type="bibr">84</xref>,<xref rid="B85-antibiotics-13-00801" ref-type="bibr">85</xref>,<xref rid="B86-antibiotics-13-00801" ref-type="bibr">86</xref>,<xref rid="B87-antibiotics-13-00801" ref-type="bibr">87</xref>,<xref rid="B88-antibiotics-13-00801" ref-type="bibr">88</xref>,<xref rid="B89-antibiotics-13-00801" ref-type="bibr">89</xref>,<xref rid="B90-antibiotics-13-00801" ref-type="bibr">90</xref>,<xref rid="B91-antibiotics-13-00801" ref-type="bibr">91</xref>,<xref rid="B92-antibiotics-13-00801" ref-type="bibr">92</xref>,<xref rid="B93-antibiotics-13-00801" ref-type="bibr">93</xref>,<xref rid="B94-antibiotics-13-00801" ref-type="bibr">94</xref>,<xref rid="B95-antibiotics-13-00801" ref-type="bibr">95</xref>,<xref rid="B96-antibiotics-13-00801" ref-type="bibr">96</xref>,<xref rid="B97-antibiotics-13-00801" ref-type="bibr">97</xref>,<xref rid="B98-antibiotics-13-00801" ref-type="bibr">98</xref>,<xref rid="B99-antibiotics-13-00801" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-13-00801" ref-type="bibr">100</xref>,<xref rid="B101-antibiotics-13-00801" ref-type="bibr">101</xref>,<xref rid="B102-antibiotics-13-00801" ref-type="bibr">102</xref>,<xref rid="B103-antibiotics-13-00801" ref-type="bibr">103</xref>,<xref rid="B104-antibiotics-13-00801" ref-type="bibr">104</xref>,<xref rid="B105-antibiotics-13-00801" ref-type="bibr">105</xref>,<xref rid="B106-antibiotics-13-00801" ref-type="bibr">106</xref>,<xref rid="B107-antibiotics-13-00801" ref-type="bibr">107</xref>,<xref rid="B108-antibiotics-13-00801" ref-type="bibr">108</xref>,<xref rid="B109-antibiotics-13-00801" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-13-00801" ref-type="bibr">110</xref>,<xref rid="B111-antibiotics-13-00801" ref-type="bibr">111</xref>,<xref rid="B112-antibiotics-13-00801" ref-type="bibr">112</xref>,<xref rid="B113-antibiotics-13-00801" ref-type="bibr">113</xref>,<xref rid="B114-antibiotics-13-00801" ref-type="bibr">114</xref>,<xref rid="B115-antibiotics-13-00801" ref-type="bibr">115</xref>,<xref rid="B116-antibiotics-13-00801" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-13-00801" ref-type="bibr">117</xref>,<xref rid="B118-antibiotics-13-00801" ref-type="bibr">118</xref>,<xref rid="B119-antibiotics-13-00801" ref-type="bibr">119</xref>,<xref rid="B120-antibiotics-13-00801" ref-type="bibr">120</xref>,<xref rid="B121-antibiotics-13-00801" ref-type="bibr">121</xref>,<xref rid="B122-antibiotics-13-00801" ref-type="bibr">122</xref>,<xref rid="B123-antibiotics-13-00801" ref-type="bibr">123</xref>,<xref rid="B124-antibiotics-13-00801" ref-type="bibr">124</xref>,<xref rid="B125-antibiotics-13-00801" ref-type="bibr">125</xref>,<xref rid="B126-antibiotics-13-00801" ref-type="bibr">126</xref>,<xref rid="B127-antibiotics-13-00801" ref-type="bibr">127</xref>,<xref rid="B128-antibiotics-13-00801" ref-type="bibr">128</xref>,<xref rid="B129-antibiotics-13-00801" ref-type="bibr">129</xref>,<xref rid="B130-antibiotics-13-00801" ref-type="bibr">130</xref>,<xref rid="B131-antibiotics-13-00801" ref-type="bibr">131</xref>,<xref rid="B132-antibiotics-13-00801" ref-type="bibr">132</xref>,<xref rid="B133-antibiotics-13-00801" ref-type="bibr">133</xref>,<xref rid="B134-antibiotics-13-00801" ref-type="bibr">134</xref>,<xref rid="B135-antibiotics-13-00801" ref-type="bibr">135</xref>,<xref rid="B136-antibiotics-13-00801" ref-type="bibr">136</xref>,<xref rid="B137-antibiotics-13-00801" ref-type="bibr">137</xref>,<xref rid="B138-antibiotics-13-00801" ref-type="bibr">138</xref>,<xref rid="B139-antibiotics-13-00801" ref-type="bibr">139</xref>,<xref rid="B140-antibiotics-13-00801" ref-type="bibr">140</xref>,<xref rid="B141-antibiotics-13-00801" ref-type="bibr">141</xref>,<xref rid="B142-antibiotics-13-00801" ref-type="bibr">142</xref>,<xref rid="B143-antibiotics-13-00801" ref-type="bibr">143</xref>,<xref rid="B144-antibiotics-13-00801" ref-type="bibr">144</xref>,<xref rid="B145-antibiotics-13-00801" ref-type="bibr">145</xref>,<xref rid="B146-antibiotics-13-00801" ref-type="bibr">146</xref>,<xref rid="B147-antibiotics-13-00801" ref-type="bibr">147</xref>,<xref rid="B148-antibiotics-13-00801" ref-type="bibr">148</xref>,<xref rid="B149-antibiotics-13-00801" ref-type="bibr">149</xref>,<xref rid="B150-antibiotics-13-00801" ref-type="bibr">150</xref>,<xref rid="B151-antibiotics-13-00801" ref-type="bibr">151</xref>,<xref rid="B152-antibiotics-13-00801" ref-type="bibr">152</xref>,<xref rid="B153-antibiotics-13-00801" ref-type="bibr">153</xref>,<xref rid="B154-antibiotics-13-00801" ref-type="bibr">154</xref>,<xref rid="B155-antibiotics-13-00801" ref-type="bibr">155</xref>,<xref rid="B156-antibiotics-13-00801" ref-type="bibr">156</xref>,<xref rid="B157-antibiotics-13-00801" ref-type="bibr">157</xref>,<xref rid="B158-antibiotics-13-00801" ref-type="bibr">158</xref>,<xref rid="B159-antibiotics-13-00801" ref-type="bibr">159</xref>,<xref rid="B160-antibiotics-13-00801" ref-type="bibr">160</xref>,<xref rid="B161-antibiotics-13-00801" ref-type="bibr">161</xref>,<xref rid="B162-antibiotics-13-00801" ref-type="bibr">162</xref>,<xref rid="B163-antibiotics-13-00801" ref-type="bibr">163</xref>,<xref rid="B164-antibiotics-13-00801" ref-type="bibr">164</xref>,<xref rid="B165-antibiotics-13-00801" ref-type="bibr">165</xref>,<xref rid="B166-antibiotics-13-00801" ref-type="bibr">166</xref>,<xref rid="B167-antibiotics-13-00801" ref-type="bibr">167</xref>,<xref rid="B168-antibiotics-13-00801" ref-type="bibr">168</xref>,<xref rid="B169-antibiotics-13-00801" ref-type="bibr">169</xref>,<xref rid="B170-antibiotics-13-00801" ref-type="bibr">170</xref>,<xref rid="B171-antibiotics-13-00801" ref-type="bibr">171</xref>,<xref rid="B172-antibiotics-13-00801" ref-type="bibr">172</xref>,<xref rid="B173-antibiotics-13-00801" ref-type="bibr">173</xref>,<xref rid="B174-antibiotics-13-00801" ref-type="bibr">174</xref>,<xref rid="B175-antibiotics-13-00801" ref-type="bibr">175</xref>,<xref rid="B176-antibiotics-13-00801" ref-type="bibr">176</xref>,<xref rid="B177-antibiotics-13-00801" ref-type="bibr">177</xref>,<xref rid="B178-antibiotics-13-00801" ref-type="bibr">178</xref>,<xref rid="B179-antibiotics-13-00801" ref-type="bibr">179</xref>,<xref rid="B180-antibiotics-13-00801" ref-type="bibr">180</xref>,<xref rid="B181-antibiotics-13-00801" ref-type="bibr">181</xref>,<xref rid="B182-antibiotics-13-00801" ref-type="bibr">182</xref>,<xref rid="B183-antibiotics-13-00801" ref-type="bibr">183</xref>,<xref rid="B184-antibiotics-13-00801" ref-type="bibr">184</xref>,<xref rid="B185-antibiotics-13-00801" ref-type="bibr">185</xref>,<xref rid="B186-antibiotics-13-00801" ref-type="bibr">186</xref>,<xref rid="B187-antibiotics-13-00801" ref-type="bibr">187</xref>,<xref rid="B188-antibiotics-13-00801" ref-type="bibr">188</xref>,<xref rid="B189-antibiotics-13-00801" ref-type="bibr">189</xref>,<xref rid="B190-antibiotics-13-00801" ref-type="bibr">190</xref>,<xref rid="B191-antibiotics-13-00801" ref-type="bibr">191</xref>,<xref rid="B192-antibiotics-13-00801" ref-type="bibr">192</xref>,<xref rid="B193-antibiotics-13-00801" ref-type="bibr">193</xref>,<xref rid="B194-antibiotics-13-00801" ref-type="bibr">194</xref>,<xref rid="B195-antibiotics-13-00801" ref-type="bibr">195</xref>,<xref rid="B196-antibiotics-13-00801" ref-type="bibr">196</xref>,<xref rid="B197-antibiotics-13-00801" ref-type="bibr">197</xref>,<xref rid="B198-antibiotics-13-00801" ref-type="bibr">198</xref>,<xref rid="B199-antibiotics-13-00801" ref-type="bibr">199</xref>,<xref rid="B200-antibiotics-13-00801" ref-type="bibr">200</xref>,<xref rid="B201-antibiotics-13-00801" ref-type="bibr">201</xref>,<xref rid="B202-antibiotics-13-00801" ref-type="bibr">202</xref>,<xref rid="B203-antibiotics-13-00801" ref-type="bibr">203</xref>,<xref rid="B204-antibiotics-13-00801" ref-type="bibr">204</xref>,<xref rid="B205-antibiotics-13-00801" ref-type="bibr">205</xref>,<xref rid="B206-antibiotics-13-00801" ref-type="bibr">206</xref>,<xref rid="B207-antibiotics-13-00801" ref-type="bibr">207</xref>,<xref rid="B208-antibiotics-13-00801" ref-type="bibr">208</xref>,<xref rid="B209-antibiotics-13-00801" ref-type="bibr">209</xref>,<xref rid="B210-antibiotics-13-00801" ref-type="bibr">210</xref>,<xref rid="B211-antibiotics-13-00801" ref-type="bibr">211</xref>,<xref rid="B212-antibiotics-13-00801" ref-type="bibr">212</xref>,<xref rid="B213-antibiotics-13-00801" ref-type="bibr">213</xref>,<xref rid="B214-antibiotics-13-00801" ref-type="bibr">214</xref>,<xref rid="B215-antibiotics-13-00801" ref-type="bibr">215</xref>,<xref rid="B216-antibiotics-13-00801" ref-type="bibr">216</xref>,<xref rid="B217-antibiotics-13-00801" ref-type="bibr">217</xref>,<xref rid="B218-antibiotics-13-00801" ref-type="bibr">218</xref>,<xref rid="B219-antibiotics-13-00801" ref-type="bibr">219</xref>,<xref rid="B220-antibiotics-13-00801" ref-type="bibr">220</xref>,<xref rid="B221-antibiotics-13-00801" ref-type="bibr">221</xref>,<xref rid="B222-antibiotics-13-00801" ref-type="bibr">222</xref>,<xref rid="B223-antibiotics-13-00801" ref-type="bibr">223</xref>,<xref rid="B224-antibiotics-13-00801" ref-type="bibr">224</xref>,<xref rid="B225-antibiotics-13-00801" ref-type="bibr">225</xref>,<xref rid="B226-antibiotics-13-00801" ref-type="bibr">226</xref>,<xref rid="B227-antibiotics-13-00801" ref-type="bibr">227</xref>,<xref rid="B228-antibiotics-13-00801" ref-type="bibr">228</xref>,<xref rid="B229-antibiotics-13-00801" ref-type="bibr">229</xref>,<xref rid="B230-antibiotics-13-00801" ref-type="bibr">230</xref>,<xref rid="B231-antibiotics-13-00801" ref-type="bibr">231</xref>,<xref rid="B232-antibiotics-13-00801" ref-type="bibr">232</xref>,<xref rid="B233-antibiotics-13-00801" ref-type="bibr">233</xref>,<xref rid="B234-antibiotics-13-00801" ref-type="bibr">234</xref>,<xref rid="B235-antibiotics-13-00801" ref-type="bibr">235</xref>,<xref rid="B236-antibiotics-13-00801" ref-type="bibr">236</xref>,<xref rid="B237-antibiotics-13-00801" ref-type="bibr">237</xref>,<xref rid="B238-antibiotics-13-00801" ref-type="bibr">238</xref>,<xref rid="B239-antibiotics-13-00801" ref-type="bibr">239</xref>,<xref rid="B240-antibiotics-13-00801" ref-type="bibr">240</xref>,<xref rid="B241-antibiotics-13-00801" ref-type="bibr">241</xref>,<xref rid="B242-antibiotics-13-00801" ref-type="bibr">242</xref>,<xref rid="B243-antibiotics-13-00801" ref-type="bibr">243</xref>,<xref rid="B244-antibiotics-13-00801" ref-type="bibr">244</xref>,<xref rid="B245-antibiotics-13-00801" ref-type="bibr">245</xref>,<xref rid="B246-antibiotics-13-00801" ref-type="bibr">246</xref>,<xref rid="B247-antibiotics-13-00801" ref-type="bibr">247</xref>,<xref rid="B248-antibiotics-13-00801" ref-type="bibr">248</xref>,<xref rid="B249-antibiotics-13-00801" ref-type="bibr">249</xref>,<xref rid="B250-antibiotics-13-00801" ref-type="bibr">250</xref>,<xref rid="B251-antibiotics-13-00801" ref-type="bibr">251</xref>,<xref rid="B252-antibiotics-13-00801" ref-type="bibr">252</xref>,<xref rid="B253-antibiotics-13-00801" ref-type="bibr">253</xref>,<xref rid="B254-antibiotics-13-00801" ref-type="bibr">254</xref>,<xref rid="B255-antibiotics-13-00801" ref-type="bibr">255</xref>,<xref rid="B256-antibiotics-13-00801" ref-type="bibr">256</xref>,<xref rid="B257-antibiotics-13-00801" ref-type="bibr">257</xref>,<xref rid="B258-antibiotics-13-00801" ref-type="bibr">258</xref>,<xref rid="B259-antibiotics-13-00801" ref-type="bibr">259</xref>,<xref rid="B260-antibiotics-13-00801" ref-type="bibr">260</xref>,<xref rid="B261-antibiotics-13-00801" ref-type="bibr">261</xref>,<xref rid="B262-antibiotics-13-00801" ref-type="bibr">262</xref>,<xref rid="B263-antibiotics-13-00801" ref-type="bibr">263</xref>,<xref rid="B264-antibiotics-13-00801" ref-type="bibr">264</xref>,<xref rid="B265-antibiotics-13-00801" ref-type="bibr">265</xref>,<xref rid="B266-antibiotics-13-00801" ref-type="bibr">266</xref>,<xref rid="B267-antibiotics-13-00801" ref-type="bibr">267</xref>,<xref rid="B268-antibiotics-13-00801" ref-type="bibr">268</xref>,<xref rid="B269-antibiotics-13-00801" ref-type="bibr">269</xref>,<xref rid="B270-antibiotics-13-00801" ref-type="bibr">270</xref>,<xref rid="B271-antibiotics-13-00801" ref-type="bibr">271</xref>,<xref rid="B272-antibiotics-13-00801" ref-type="bibr">272</xref>,<xref rid="B273-antibiotics-13-00801" ref-type="bibr">273</xref>,<xref rid="B274-antibiotics-13-00801" ref-type="bibr">274</xref>,<xref rid="B275-antibiotics-13-00801" ref-type="bibr">275</xref>,<xref rid="B276-antibiotics-13-00801" ref-type="bibr">276</xref>,<xref rid="B277-antibiotics-13-00801" ref-type="bibr">277</xref>,<xref rid="B278-antibiotics-13-00801" ref-type="bibr">278</xref>,<xref rid="B279-antibiotics-13-00801" ref-type="bibr">279</xref>,<xref rid="B280-antibiotics-13-00801" ref-type="bibr">280</xref>,<xref rid="B281-antibiotics-13-00801" ref-type="bibr">281</xref>,<xref rid="B282-antibiotics-13-00801" ref-type="bibr">282</xref>,<xref rid="B283-antibiotics-13-00801" ref-type="bibr">283</xref>,<xref rid="B284-antibiotics-13-00801" ref-type="bibr">284</xref>,<xref rid="B285-antibiotics-13-00801" ref-type="bibr">285</xref>,<xref rid="B286-antibiotics-13-00801" ref-type="bibr">286</xref>,<xref rid="B287-antibiotics-13-00801" ref-type="bibr">287</xref>,<xref rid="B288-antibiotics-13-00801" ref-type="bibr">288</xref>,<xref rid="B289-antibiotics-13-00801" ref-type="bibr">289</xref>,<xref rid="B290-antibiotics-13-00801" ref-type="bibr">290</xref>,<xref rid="B291-antibiotics-13-00801" ref-type="bibr">291</xref>,<xref rid="B292-antibiotics-13-00801" ref-type="bibr">292</xref>,<xref rid="B293-antibiotics-13-00801" ref-type="bibr">293</xref>,<xref rid="B294-antibiotics-13-00801" ref-type="bibr">294</xref>,<xref rid="B295-antibiotics-13-00801" ref-type="bibr">295</xref>,<xref rid="B296-antibiotics-13-00801" ref-type="bibr">296</xref>,<xref rid="B297-antibiotics-13-00801" ref-type="bibr">297</xref>,<xref rid="B298-antibiotics-13-00801" ref-type="bibr">298</xref>,<xref rid="B299-antibiotics-13-00801" ref-type="bibr">299</xref>,<xref rid="B300-antibiotics-13-00801" ref-type="bibr">300</xref>,<xref rid="B301-antibiotics-13-00801" ref-type="bibr">301</xref>,<xref rid="B302-antibiotics-13-00801" ref-type="bibr">302</xref>,<xref rid="B303-antibiotics-13-00801" ref-type="bibr">303</xref>,<xref rid="B304-antibiotics-13-00801" ref-type="bibr">304</xref>,<xref rid="B305-antibiotics-13-00801" ref-type="bibr">305</xref>,<xref rid="B306-antibiotics-13-00801" ref-type="bibr">306</xref>,<xref rid="B307-antibiotics-13-00801" ref-type="bibr">307</xref>,<xref rid="B308-antibiotics-13-00801" ref-type="bibr">308</xref>,<xref rid="B309-antibiotics-13-00801" ref-type="bibr">309</xref>] are the studies included in the review, that are cited in the <xref rid="app1-antibiotics-13-00801" ref-type="app">Supplementary Materials</xref>.</p><supplementary-material id="antibiotics-13-00801-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="antibiotics-13-00801-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, L.G.-M.; methodology, L.G.-M.; formal analysis, A.P.-D., B.Z.-T. and J.R.-R.; data curation, L.G.-M.; writing&#8212;original draft preparation, L.G.-M., B.Z.-T., P.V.-A. and J.R.-R.; writing&#8212;review and editing, C.B. and D.S.; visualization, D.S., O.H.T. and P.V.-A.; supervision, D.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki and approved by the Hospital Sant Pau Ethical Committee (ID: Reference No: - IIBSP-TER-2024-26).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are available under reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-13-00801"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alhazzani</surname><given-names>W.</given-names></name><name name-style="western"><surname>Antonelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coopersmith</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>French</surname><given-names>C.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Mcintyre</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ostermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>H.C.</given-names></name><etal/></person-group><article-title>Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021</article-title><source>Intensive Care Med.</source><year>2021</year><volume>47</volume><fpage>1181</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1007/s00134-021-06506-y</pub-id><pub-id pub-id-type="pmid">34599691</pub-id><pub-id pub-id-type="pmcid">PMC8486643</pub-id></element-citation></ref><ref id="B2-antibiotics-13-00801"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development</article-title><source>Semin. Respir. Crit. Care Med.</source><year>2015</year><volume>36</volume><fpage>136</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1398490</pub-id><pub-id pub-id-type="pmid">25643277</pub-id></element-citation></ref><ref id="B3-antibiotics-13-00801"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhaese</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Vooren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boelens</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.</given-names></name></person-group><article-title>Therapeutic drug monitoring of &#946;-lactam antibiotics in the ICU</article-title><source>Expert Rev. Anti-infective Ther.</source><year>2020</year><volume>18</volume><fpage>1155</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1788387</pub-id><pub-id pub-id-type="pmid">32597263</pub-id></element-citation></ref><ref id="B4-antibiotics-13-00801"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Blasco</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Alfaro</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Reinoso</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Mestre</surname><given-names>M.J.G.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A.</given-names></name></person-group><source>An&#225;lisis Farmacocin&#233;tico-Farmacodin&#225;mico en Microbiolog&#237;a: Herramienta para Evaluar el Tratamiento Antimicrobiano Enfermedades Infecciosas y Microbiologia Clinica</source><publisher-name>Elsevier Doyma</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2015</year><volume>Volume 33</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eimc.2013.04.023</pub-id><pub-id pub-id-type="pmid">23850188</pub-id></element-citation></ref><ref id="B5-antibiotics-13-00801"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizk</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Bhavnani</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dane</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eakin</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Guina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Tomayko</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><pub-id pub-id-type="doi">10.1128/AAC.02309-18</pub-id><pub-id pub-id-type="pmcid">PMC6496063</pub-id><pub-id pub-id-type="pmid">30833427</pub-id></element-citation></ref><ref id="B6-antibiotics-13-00801"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scaglione</surname><given-names>F.</given-names></name><name name-style="western"><surname>Paraboni</surname><given-names>L.</given-names></name></person-group><article-title>Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection</article-title><source>Expert Rev. Anti-infective Ther.</source><year>2006</year><volume>4</volume><fpage>479</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1586/14787210.4.3.479</pub-id><pub-id pub-id-type="pmid">16771624</pub-id></element-citation></ref><ref id="B7-antibiotics-13-00801"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambrose</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Bhavnani</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Rubino</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Louie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gumbo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A.</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>G.L.</given-names></name></person-group><article-title>Antimicrobial Resistance: Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It&#8217;s Not Just for Mice Anymore</article-title><source>Clin. Infect. Dis.</source><year>2007</year><volume>44</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1086/510079</pub-id><pub-id pub-id-type="pmid">17143821</pub-id></element-citation></ref><ref id="B8-antibiotics-13-00801"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liebchen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Paal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taubert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irlbeck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>I.</given-names></name></person-group><article-title>The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome</article-title><source>J. Intensive Care</source><year>2020</year><volume>8</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.1186/s40560-020-00504-w</pub-id><pub-id pub-id-type="pmid">33292582</pub-id><pub-id pub-id-type="pmcid">PMC7686672</pub-id></element-citation></ref><ref id="B9-antibiotics-13-00801"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>T&#228;ngd&#233;n</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Felton</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Marchand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Br&#252;ggemann</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Bulitta</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Theuretzbacher</surname><given-names>U.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>B.T.</given-names></name><etal/></person-group><article-title>The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections</article-title><source>Intensive Care Med.</source><year>2017</year><volume>43</volume><fpage>1021</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1007/s00134-017-4780-6</pub-id><pub-id pub-id-type="pmid">28409203</pub-id></element-citation></ref><ref id="B10-antibiotics-13-00801"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>J.-W.C.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bracht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>J.-A.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sjovall</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper<sub>#</sub></article-title><source>Intensive Care Med.</source><year>2020</year><volume>46</volume><fpage>1127</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1007/s00134-020-06050-1</pub-id><pub-id pub-id-type="pmid">32383061</pub-id><pub-id pub-id-type="pmcid">PMC7223855</pub-id></element-citation></ref><ref id="B11-antibiotics-13-00801"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilhaumou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benaboud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bennis</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dahyot-Fizelier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dailly</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gandia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Goutelle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lefeuvre</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mongardon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Roger</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Optimization of the treatment with be-ta-lactam antibiotics in critically ill patients&#8212;Guidelines from the French Society of Pharmacology and Therapeutics (Soci&#233;t&#233; Fran-&#231;aise de Pharmacologie et Th&#233;rapeutique&#8212;SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci&#233;t&#233; Fran&#231;aise d&#8217;Anesth&#233;sie et R&#233;animation&#8212;SFAR)</article-title><source>Crit. Care</source><year>2019</year><volume>23</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">30925922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-019-2378-9</pub-id><pub-id pub-id-type="pmcid">PMC6441232</pub-id></element-citation></ref><ref id="B12-antibiotics-13-00801"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sta&#353;ek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ko&#269;&#237;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Klu&#269;ka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klabusayov&#225;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wiewiorka</surname><given-names>O.</given-names></name><name name-style="western"><surname>Stra&#353;ilov&#225;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Be&#328;ovsk&#225;</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#352;kardov&#225;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mal&#225;ska</surname><given-names>J.</given-names></name></person-group><article-title>Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients&#8212;A Narrative Review</article-title><source>Antibiotics</source><year>2023</year><volume>12</volume><elocation-id>568</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12030568</pub-id><pub-id pub-id-type="pmid">36978435</pub-id><pub-id pub-id-type="pmcid">PMC10044408</pub-id></element-citation></ref><ref id="B13-antibiotics-13-00801"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Expert consensus statement on therapeutic drug monitoring and individuali-zation of linezolid</article-title><source>Front. Public Health</source><year>2022</year><volume>10</volume><elocation-id>967311</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.967311</pub-id><pub-id pub-id-type="pmid">36033811</pub-id><pub-id pub-id-type="pmcid">PMC9399604</pub-id></element-citation></ref><ref id="B14-antibiotics-13-00801"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Villois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Briscoe</surname><given-names>S.</given-names></name><name name-style="western"><surname>McWhinney</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nunez-Nunez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ungerer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>&#946;-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>75</volume><fpage>429</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz437</pub-id><pub-id pub-id-type="pmid">31665353</pub-id></element-citation></ref><ref id="B15-antibiotics-13-00801"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name><name name-style="western"><surname>Viale</surname><given-names>P.</given-names></name><name name-style="western"><surname>Furlanut</surname><given-names>M.</given-names></name></person-group><article-title>Antimicrobial Therapy in Critically Ill Patients A Review of Pathophysiological Conditions Responsible for Altered Disposition and Pharmacokinetic Variability</article-title><source>Clin. Pharmacokinet.</source><year>2005</year><volume>44</volume><fpage>1009</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.2165/00003088-200544100-00002</pub-id><pub-id pub-id-type="pmid">16176116</pub-id></element-citation></ref><ref id="B16-antibiotics-13-00801"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scaglione</surname><given-names>F.</given-names></name><name name-style="western"><surname>Paraboni</surname><given-names>L.</given-names></name></person-group><article-title>Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: Setting appropriate dosing regimens</article-title><source>Int. J. Antimicrob. Agents</source><year>2008</year><volume>32</volume><fpage>294</fpage><lpage>301.e7</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2008.03.015</pub-id><pub-id pub-id-type="pmid">18621508</pub-id></element-citation></ref><ref id="B17-antibiotics-13-00801"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veiga</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>J.-A.</given-names></name></person-group><article-title>Pharmacokinetics&#8211;pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients</article-title><source>Crit. Care</source><year>2018</year><volume>22</volume><fpage>233</fpage><pub-id pub-id-type="doi">10.1186/s13054-018-2155-1</pub-id><pub-id pub-id-type="pmid">30244674</pub-id><pub-id pub-id-type="pmcid">PMC6151903</pub-id></element-citation></ref><ref id="B18-antibiotics-13-00801"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulldemolins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nuvials</surname><given-names>X.</given-names></name><name name-style="western"><surname>Palomar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Masclans</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J.</given-names></name></person-group><article-title>Appropriateness is Critical</article-title><source>Crit. Care Clin.</source><year>2011</year><volume>27</volume><fpage>35</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ccc.2010.09.007</pub-id><pub-id pub-id-type="pmid">21144985</pub-id></element-citation></ref><ref id="B19-antibiotics-13-00801"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blot</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name></person-group><article-title>The effect of pathophysiology on pharmacokinetics in the critically ill patient &#8212; Concepts appraised by the example of antimicrobial agents</article-title><source>Adv. Drug Deliv. Rev.</source><year>2014</year><volume>77</volume><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2014.07.006</pub-id><pub-id pub-id-type="pmid">25038549</pub-id></element-citation></ref><ref id="B20-antibiotics-13-00801"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cotta</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name></person-group><article-title>Antibiotic Dose Optimization in Critically Ill Patients</article-title><source>Med. Intensive</source><year>2015</year><volume>39</volume><fpage>563</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/j.medin.2015.07.009</pub-id><pub-id pub-id-type="pmid">26415688</pub-id></element-citation></ref><ref id="B21-antibiotics-13-00801"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Vinks</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Felton</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions</article-title><source>Lancet Infect. Dis.</source><year>2014</year><volume>14</volume><fpage>498</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70036-2</pub-id><pub-id pub-id-type="pmid">24768475</pub-id><pub-id pub-id-type="pmcid">PMC4181663</pub-id></element-citation></ref><ref id="B22-antibiotics-13-00801"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulldemolins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name></person-group><article-title>The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients</article-title><source>Clin. Pharmacokinet.</source><year>2011</year><volume>50</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.2165/11539220-000000000-00000</pub-id><pub-id pub-id-type="pmid">21142293</pub-id></element-citation></ref><ref id="B23-antibiotics-13-00801"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contejean</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maillard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Canou&#239;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kern&#233;is</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fantin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bouscary</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parize</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garcia-Vidal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Charlier</surname><given-names>C.</given-names></name></person-group><article-title>Advances in antibacterial treatment of adults with high-risk febrile neutropenia</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>78</volume><fpage>2109</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/jac/dkad166</pub-id><pub-id pub-id-type="pmid">37259598</pub-id></element-citation></ref><ref id="B24-antibiotics-13-00801"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alobaid</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Hites</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review</article-title><source>Int. J. Antimicrob. Agents</source><year>2016</year><volume>47</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.01.009</pub-id><pub-id pub-id-type="pmid">26988339</pub-id></element-citation></ref><ref id="B25-antibiotics-13-00801"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miglis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Kuti</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Van Wart</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>M.H.</given-names></name></person-group><article-title>Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: A &#8216;Goldilocks&#8217; window</article-title><source>Int. J. Antimicrob. Agents</source><year>2017</year><volume>50</volume><fpage>487</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.04.023</pub-id><pub-id pub-id-type="pmid">28668683</pub-id></element-citation></ref><ref id="B26-antibiotics-13-00801"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewoldt</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smeets</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Gommers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H.</given-names></name></person-group><article-title>The impact of sepsis on hepatic drug metabolism in critically ill patients: A narrative review</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2022</year><volume>18</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1080/17425255.2022.2106215</pub-id><pub-id pub-id-type="pmid">35912845</pub-id></element-citation></ref><ref id="B27-antibiotics-13-00801"><label>27.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Pistolesi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mario</surname><given-names>F.</given-names></name><name name-style="western"><surname>Di Regolisti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cantarelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fiaccadori</surname><given-names>E.</given-names></name></person-group><article-title>A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy [Internet]</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://aac.asm.org/" ext-link-type="uri">http://aac.asm.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-18">(accessed on 18 July 2024)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00583-19</pub-id><pub-id pub-id-type="pmcid">PMC6658763</pub-id><pub-id pub-id-type="pmid">31109983</pub-id></element-citation></ref><ref id="B28-antibiotics-13-00801"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Under-going Continuous Renal Replacement Therapy with Imipenem</article-title><source>Clin. Ther.</source><year>2020</year><volume>42</volume><fpage>1564</fpage><lpage>1577.e8</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2020.06.010</pub-id><pub-id pub-id-type="pmid">32741646</pub-id></element-citation></ref><ref id="B29-antibiotics-13-00801"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peluso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Hites</surname><given-names>M.</given-names></name></person-group><article-title>The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2021</year><volume>17</volume><fpage>543</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1080/17425255.2021.1902985</pub-id><pub-id pub-id-type="pmid">33733979</pub-id></element-citation></ref><ref id="B30-antibiotics-13-00801"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name></person-group><article-title>Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need?</article-title><source>A Practical Ap-proach for Guiding Dose Optimization of Novel Antibiotics. Clin. Pharmacokinet.</source><year>2021</year><volume>60</volume><fpage>1271</fpage><lpage>1289</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-021-01040-y</pub-id><pub-id pub-id-type="pmcid">PMC8505328</pub-id><pub-id pub-id-type="pmid">34125420</pub-id></element-citation></ref><ref id="B31-antibiotics-13-00801"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Rhie</surname><given-names>S.J.</given-names></name></person-group><article-title>Optimal antipseudomonal &#946;-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT</article-title><source>J. Crit. Care</source><year>2022</year><volume>72</volume><fpage>154172</fpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2022.154172</pub-id><pub-id pub-id-type="pmid">36270240</pub-id></element-citation></ref><ref id="B32-antibiotics-13-00801"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pharmacokinetics and Pharmacodynamics of Linezolid in Patients With Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>221</volume><fpage>S279</fpage><lpage>S287</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz566</pub-id><pub-id pub-id-type="pmid">32176792</pub-id></element-citation></ref><ref id="B33-antibiotics-13-00801"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Briscoe</surname><given-names>S.</given-names></name><name name-style="western"><surname>McWhinney</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ally</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ungerer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: Direct measurement of unbound drug concentrations to achieve appropriate drug exposures</article-title><source>J. Antimicrob. Chemother.</source><year>2018</year><volume>73</volume><fpage>3087</fpage><lpage>3094</lpage><pub-id pub-id-type="doi">10.1093/jac/dky314</pub-id><pub-id pub-id-type="pmid">30137377</pub-id></element-citation></ref><ref id="B34-antibiotics-13-00801"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taccone</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Laterre</surname><given-names>P.-F.</given-names></name><name name-style="western"><surname>Dugernier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spapen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Delattre</surname><given-names>I.</given-names></name><name name-style="western"><surname>Witebolle</surname><given-names>X.</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Layeux</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wallemacq</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>J.-L.</given-names></name><etal/></person-group><article-title>Insufficient &#946;-lactam concentrations in the early phase of severe sepsis and septic shock</article-title><source>Crit. Care</source><year>2010</year><volume>14</volume><fpage>R126</fpage><pub-id pub-id-type="doi">10.1186/cc9091</pub-id><pub-id pub-id-type="pmid">20594297</pub-id><pub-id pub-id-type="pmcid">PMC2945087</pub-id></element-citation></ref><ref id="B35-antibiotics-13-00801"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luyt</surname><given-names>C.-E.</given-names></name><name name-style="western"><surname>Br&#233;chot</surname><given-names>N.</given-names></name><name name-style="western"><surname>Trouillet</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Chastre</surname><given-names>J.</given-names></name></person-group><article-title>Antibiotic stewardship in the intensive care unit</article-title><source>Crit. Care</source><year>2014</year><volume>18</volume><fpage>480</fpage><pub-id pub-id-type="doi">10.1186/s13054-014-0480-6</pub-id><pub-id pub-id-type="pmid">25405992</pub-id><pub-id pub-id-type="pmcid">PMC4281952</pub-id></element-citation></ref><ref id="B36-antibiotics-13-00801"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdulla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>N.G.M.</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bahmany</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ewoldt</surname><given-names>T.M.J.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gommers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.C.P.</given-names></name></person-group><article-title>Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: A two-center prospective study (EXPAT)</article-title><source>Crit. Care</source><year>2020</year><volume>24</volume><fpage>558</fpage><pub-id pub-id-type="doi">10.1186/s13054-020-03272-z</pub-id><pub-id pub-id-type="pmid">32933574</pub-id><pub-id pub-id-type="pmcid">PMC7493358</pub-id></element-citation></ref><ref id="B37-antibiotics-13-00801"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Waele</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaukonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koulenti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Montravers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Risk factors for target non-attainment during empirical treatment with &#946;-lactam antibiotics in critically ill patients</article-title><source>Intensive Care Med.</source><year>2014</year><volume>40</volume><fpage>1340</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1007/s00134-014-3403-8</pub-id><pub-id pub-id-type="pmid">25053248</pub-id></element-citation></ref><ref id="B38-antibiotics-13-00801"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaukonen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Koulenti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Montravers</surname><given-names>P.</given-names></name><etal/></person-group><article-title>DALI: Defining antibiotic levels in intensive care unit patients: Are current &#223;-lactam antibiotic doses sufficient for critically ill patients?</article-title><source>Clin. Infect. Dis.</source><year>2014</year><volume>58</volume><fpage>1072</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu027</pub-id><pub-id pub-id-type="pmid">24429437</pub-id></element-citation></ref><ref id="B39-antibiotics-13-00801"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charmillon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Novy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Agrinier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kimmoun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Demor&#233;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dellamonica</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pulcini</surname><given-names>C.</given-names></name></person-group><article-title>The ANTIBIOPERF study: A nationwide cross-sectional survey about practices for &#946;-lactam administration and therapeutic drug monitoring among critically ill patients in France</article-title><source>Clin. Microbiol. Infect.</source><year>2016</year><volume>22</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.04.019</pub-id><pub-id pub-id-type="pmid">27145210</pub-id></element-citation></ref><ref id="B40-antibiotics-13-00801"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Tabah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cotta</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Sandaradura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kanji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Imani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elhadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luque-Pardos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schellack</surname><given-names>N.</given-names></name><etal/></person-group><article-title>International survey of antibiotic dosing and monitoring in adult intensive care units</article-title><source>Crit. Care</source><year>2023</year><volume>27</volume><fpage>241</fpage><pub-id pub-id-type="doi">10.1186/s13054-023-04527-1</pub-id><pub-id pub-id-type="pmid">37331935</pub-id><pub-id pub-id-type="pmcid">PMC10278304</pub-id></element-citation></ref><ref id="B41-antibiotics-13-00801"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Konicki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>D.J.E.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.</given-names></name><collab>On behalf of the IATDMCT Antimicrobial Scientific Committee</collab></person-group><article-title>Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics</article-title><source>Ther. Drug Monit.</source><year>2020</year><volume>42</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000710</pub-id><pub-id pub-id-type="pmid">31652190</pub-id></element-citation></ref><ref id="B42-antibiotics-13-00801"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Waele</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Carrette</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carlier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stove</surname><given-names>V.</given-names></name><name name-style="western"><surname>Boelens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Claeys</surname><given-names>G.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hoste</surname><given-names>E.</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Decruyenaere</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: A randomised controlled trial</article-title><source>Intensive Care Med.</source><year>2013</year><volume>40</volume><fpage>380</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1007/s00134-013-3187-2</pub-id><pub-id pub-id-type="pmid">24356862</pub-id></element-citation></ref><ref id="B43-antibiotics-13-00801"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steffens</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Nichelle</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Brucker</surname><given-names>N.</given-names></name></person-group><article-title>Meropenem use and therapeutic drug monitoring in clinical practice: A literature review</article-title><source>J. Clin. Pharm. Ther.</source><year>2021</year><volume>46</volume><fpage>610</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1111/jcpt.13369</pub-id><pub-id pub-id-type="pmid">33533509</pub-id></element-citation></ref><ref id="B44-antibiotics-13-00801"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wicha</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>M&#228;rtson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Minichmayr</surname><given-names>I.K.</given-names></name></person-group><article-title>The International Society of Anti-Infective Pharmacology (ISAP), the PK/PD study group of the European Society of Clinical Microbiology, Infectious Diseases (EPASG) From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics</article-title><source>Clin. Pharmacol. Ther.</source><year>2021</year><volume>109</volume><fpage>928</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1002/cpt.2202</pub-id><pub-id pub-id-type="pmid">33565627</pub-id></element-citation></ref><ref id="B45-antibiotics-13-00801"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osorio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garz&#243;n</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jaimes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bustos</surname><given-names>R.-H.</given-names></name></person-group><article-title>Impact on Antibiotic Resistance, Therapeutic Success, and Control of Side Effects in Therapeutic Drug Monitoring (TDM) of Daptomycin: A Scoping Review</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>263</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10030263</pub-id><pub-id pub-id-type="pmid">33807617</pub-id><pub-id pub-id-type="pmcid">PMC8001274</pub-id></element-citation></ref><ref id="B46-antibiotics-13-00801"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falcone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cassetta</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Lappa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tritapepe</surname><given-names>L.</given-names></name><name name-style="western"><surname>D'Ettorre</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fallani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Venditti</surname><given-names>M.</given-names></name></person-group><article-title>Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: Is therapeutic drug monitoring necessary?</article-title><source>J. Infect. Chemother.</source><year>2013</year><volume>19</volume><fpage>732</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1007/s10156-013-0559-z</pub-id><pub-id pub-id-type="pmid">23361566</pub-id></element-citation></ref><ref id="B47-antibiotics-13-00801"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valerio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alcal&#225;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garc&#237;a-Gonz&#225;lez</surname><given-names>X.</given-names></name><name name-style="western"><surname>Burillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanjurjo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bouza</surname><given-names>E.</given-names></name></person-group><article-title>Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e00687-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.00687-17</pub-id><pub-id pub-id-type="pmid">28739788</pub-id><pub-id pub-id-type="pmcid">PMC5610525</pub-id></element-citation></ref><ref id="B48-antibiotics-13-00801"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Valerio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cercenado</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garc&#237;a-Gonz&#225;lez</surname><given-names>X.</given-names></name><name name-style="western"><surname>Burillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#225;nchez-Somolinos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ju&#225;rez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verde</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bouza</surname><given-names>E.</given-names></name></person-group><article-title>Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>53</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.09.015</pub-id><pub-id pub-id-type="pmid">30243587</pub-id></element-citation></ref><ref id="B49-antibiotics-13-00801"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Egi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kano</surname><given-names>K.-I.</given-names></name><name name-style="western"><surname>Ohshima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>T.-A.</given-names></name></person-group><article-title>Efficacy of therapeutic drug monitoring-based antibiotic regimen in critically ill patients: A systematic review and meta-analysis of randomized controlled trials</article-title><source>J. Intensive Care</source><year>2023</year><volume>11</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s40560-023-00699-8</pub-id><pub-id pub-id-type="pmid">37936203</pub-id><pub-id pub-id-type="pmcid">PMC10631080</pub-id></element-citation></ref><ref id="B50-antibiotics-13-00801"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangalore</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ashok</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peel</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>A Udy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peleg</surname><given-names>A.Y.</given-names></name></person-group><article-title>Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>75</volume><fpage>1848</fpage><lpage>1860</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac506</pub-id><pub-id pub-id-type="pmid">35731853</pub-id><pub-id pub-id-type="pmcid">PMC9662173</pub-id></element-citation></ref><ref id="B51-antibiotics-13-00801"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Shaer</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Rubido</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cherabuddi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Venugopalan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Klinker</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peloquin</surname><given-names>C.</given-names></name></person-group><article-title>Early therapeutic monitoring of &#946;-lactams and associated therapy outcomes in critically ill patients</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>3644</fpage><lpage>3651</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa359</pub-id><pub-id pub-id-type="pmid">32910809</pub-id></element-citation></ref><ref id="B52-antibiotics-13-00801"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewoldt</surname><given-names>T.M.J.</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rietdijk</surname><given-names>W.J.R.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>B.C.M.</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>N.G.M.</given-names></name><name name-style="western"><surname>Purmer</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>van Vliet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wils</surname><given-names>E.-J.</given-names></name><name name-style="western"><surname>Haringman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: A multicentre randomised clinical trial</article-title><source>Intensive Care Med.</source><year>2022</year><volume>48</volume><fpage>1760</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1007/s00134-022-06921-9</pub-id><pub-id pub-id-type="pmid">36350354</pub-id><pub-id pub-id-type="pmcid">PMC9645317</pub-id></element-citation></ref><ref id="B53-antibiotics-13-00801"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>on behalf of the TARGET Study Group</collab><name name-style="western"><surname>Hagel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fiedler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hohn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brinkmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>O.R.</given-names></name><name name-style="western"><surname>Hoyer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schlattmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kiehntopf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): A prospective, multi-centre, randomised controlled trial</article-title><source>Trials</source><year>2019</year><volume>20</volume><fpage>330</fpage><pub-id pub-id-type="doi">10.1186/s13063-019-3437-x</pub-id><pub-id pub-id-type="pmid">31171029</pub-id><pub-id pub-id-type="pmcid">PMC6554958</pub-id></element-citation></ref><ref id="B54-antibiotics-13-00801"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mannan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Robey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kumarendran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bladon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mathioudakis</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Ogungbenro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dark</surname><given-names>P.</given-names></name><name name-style="western"><surname>Felton</surname><given-names>T.W.</given-names></name></person-group><article-title>Covariates in population pharmacokinetic studies of critically ill adults receiving &#946;-lactam antimicrobials: A systematic review and narrative synthesis</article-title><source>JAC-Antimicrobial Resist.</source><year>2023</year><volume>6</volume><fpage>dlae030</fpage><pub-id pub-id-type="doi">10.1093/jacamr/dlae030</pub-id><pub-id pub-id-type="pmid">38410250</pub-id><pub-id pub-id-type="pmcid">PMC10895699</pub-id></element-citation></ref><ref id="B55-antibiotics-13-00801"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name></person-group><article-title>Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: A systematic review and meta-analysis</article-title><source>Crit. Care</source><year>2024</year><volume>28</volume><fpage>123</fpage><pub-id pub-id-type="doi">10.1186/s13054-024-04911-5</pub-id><pub-id pub-id-type="pmid">38627763</pub-id><pub-id pub-id-type="pmcid">PMC11020314</pub-id></element-citation></ref><ref id="B56-antibiotics-13-00801"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varghese</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name></person-group><article-title>Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic Shock</article-title><source>Crit. Care Clin.</source><year>2011</year><volume>27</volume><fpage>19</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.ccc.2010.09.006</pub-id><pub-id pub-id-type="pmid">21144984</pub-id></element-citation></ref><ref id="B57-antibiotics-13-00801"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hites</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>F.S.</given-names></name></person-group><article-title>Optimization of antibiotic therapy in the obese, critically ill patient</article-title><source>Reanim.</source><year>2015</year><volume>24</volume><fpage>278</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1007/s13546-015-1060-8</pub-id></element-citation></ref><ref id="B58-antibiotics-13-00801"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name><name name-style="western"><surname>Furlanut</surname><given-names>M.</given-names></name><name name-style="western"><surname>Negri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pavan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Crapis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cristini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Viale</surname><given-names>P.</given-names></name></person-group><article-title>Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>1863</fpage><lpage>1867</lpage><pub-id pub-id-type="doi">10.1128/AAC.01149-08</pub-id><pub-id pub-id-type="pmid">19223642</pub-id><pub-id pub-id-type="pmcid">PMC2681515</pub-id></element-citation></ref><ref id="B59-antibiotics-13-00801"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Akl</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation></ref><ref id="B60-antibiotics-13-00801"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ensom</surname><given-names>M.H.H.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement</article-title><source>Clin. Pharmacokinet.</source><year>2015</year><volume>54</volume><fpage>783</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0236-8</pub-id><pub-id pub-id-type="pmid">25637173</pub-id></element-citation></ref><ref id="B61-antibiotics-13-00801"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitehouse</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cepeda</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aarons</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nalda-Molina</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tobin</surname><given-names>C.</given-names></name><name name-style="western"><surname>MacGowan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kibbler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pharmacokinetic studies of linezolid and teicoplanin in the critically ill</article-title><source>J. Antimicrob. Chemother.</source><year>2005</year><volume>55</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1093/jac/dki014</pub-id><pub-id pub-id-type="pmid">15705641</pub-id></element-citation></ref><ref id="B62-antibiotics-13-00801"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkhardt</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Katterwe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Majcher-Peszynska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Drewelow</surname><given-names>B.</given-names></name><name name-style="western"><surname>Derendorf</surname><given-names>H.</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T.</given-names></name></person-group><article-title>Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: Pharmacokinetics with special consideration of free-drug concentration</article-title><source>J. Antimicrob. Chemother.</source><year>2006</year><volume>59</volume><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl485</pub-id><pub-id pub-id-type="pmid">17185298</pub-id></element-citation></ref><ref id="B63-antibiotics-13-00801"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roos</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>C.M.J.</given-names></name></person-group><article-title>Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria</article-title><source>Intensive Care Med.</source><year>2007</year><volume>33</volume><fpage>781</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1007/s00134-007-0573-7</pub-id><pub-id pub-id-type="pmid">17342515</pub-id></element-citation></ref><ref id="B64-antibiotics-13-00801"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Field</surname><given-names>J.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whitbread</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tallot</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>C.M.J.</given-names></name></person-group><article-title>Using Population Pharmacokinetics To Determine Gentamicin Dosing during Extended Daily Diafiltration in Critically Ill Patients with Acute Kidney Injury</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>3635</fpage><lpage>3640</lpage><pub-id pub-id-type="doi">10.1128/AAC.00222-10</pub-id><pub-id pub-id-type="pmid">20547809</pub-id><pub-id pub-id-type="pmcid">PMC2934958</pub-id></element-citation></ref><ref id="B65-antibiotics-13-00801"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asin-Prieto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rodriguez-Gascon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Troconiz</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Soraluce</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maynar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanchez-Izquierdo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Isla</surname><given-names>A.</given-names></name></person-group><article-title>Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: Application to pharmacokinetic/pharmacodynamic analysis</article-title><source>J. Antimicrob. Chemother.</source><year>2013</year><volume>69</volume><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1093/jac/dkt304</pub-id><pub-id pub-id-type="pmid">23908259</pub-id></element-citation></ref><ref id="B66-antibiotics-13-00801"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escobar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Andresen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Regueira</surname><given-names>T.</given-names></name><name name-style="western"><surname>B&#243;rquez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration</article-title><source>Int. J. Antimicrob. Agents</source><year>2014</year><volume>44</volume><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.03.009</pub-id><pub-id pub-id-type="pmid">24837847</pub-id></element-citation></ref><ref id="B67-antibiotics-13-00801"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couffignal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pajot</surname><given-names>O.</given-names></name><name name-style="western"><surname>Laou&#233;nan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Burdet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Foucrier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armand-Lefevre</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mentr&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Massias</surname><given-names>L.</given-names></name></person-group><article-title>Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens</article-title><source>Br. J. Clin. Pharmacol.</source><year>2014</year><volume>78</volume><fpage>1022</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1111/bcp.12435</pub-id><pub-id pub-id-type="pmid">24903189</pub-id><pub-id pub-id-type="pmcid">PMC4243876</pub-id></element-citation></ref><ref id="B68-antibiotics-13-00801"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Noe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Stove</surname><given-names>V.</given-names></name><name name-style="western"><surname>Verstraete</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.J.</given-names></name></person-group><article-title>Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: Non-standard dosing approaches are required to achieve therapeutic exposures</article-title><source>J. Antimicrob. Chemother.</source><year>2014</year><volume>69</volume><fpage>2797</fpage><lpage>2803</lpage><pub-id pub-id-type="doi">10.1093/jac/dku195</pub-id><pub-id pub-id-type="pmid">24917580</pub-id></element-citation></ref><ref id="B69-antibiotics-13-00801"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hornuss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>C.</given-names></name><name name-style="western"><surname>D&#246;bbeler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nagel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Holdt</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Bruegel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Grabein</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Variability of linezolid concentrations after standard dosing in critically ill patients: A prospective observational study</article-title><source>Crit. Care</source><year>2014</year><volume>18</volume><fpage>R148</fpage><pub-id pub-id-type="doi">10.1186/cc13984</pub-id><pub-id pub-id-type="pmid">25011656</pub-id><pub-id pub-id-type="pmcid">PMC4227093</pub-id></element-citation></ref><ref id="B70-antibiotics-13-00801"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luque</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alvarez-Lerma</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferr&#225;ndez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Campillo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Horcajada</surname><given-names>J.</given-names></name><name name-style="western"><surname>Basas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.</given-names></name></person-group><article-title>Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections</article-title><source>Int. J. Antimicrob. Agents</source><year>2014</year><volume>44</volume><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.07.001</pub-id><pub-id pub-id-type="pmid">25216547</pub-id></element-citation></ref><ref id="B71-antibiotics-13-00801"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulldemolins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Llaurado-Serra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vaquer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Pontes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;n-Loeches</surname><given-names>I.</given-names></name></person-group><article-title>Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>5520</fpage><lpage>5528</lpage><pub-id pub-id-type="doi">10.1128/AAC.00712-15</pub-id><pub-id pub-id-type="pmid">26124172</pub-id><pub-id pub-id-type="pmcid">PMC4538468</pub-id></element-citation></ref><ref id="B72-antibiotics-13-00801"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kees</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Minichmayr</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Moritz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Kees</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C.</given-names></name><name name-style="western"><surname>Steinke</surname><given-names>T.</given-names></name></person-group><article-title>Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients</article-title><source>J. Clin. Pharmacol.</source><year>2015</year><volume>56</volume><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1002/jcph.600</pub-id><pub-id pub-id-type="pmid">26222202</pub-id></element-citation></ref><ref id="B73-antibiotics-13-00801"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A.N.A.</given-names></name><name name-style="western"><surname>Mat-Nor</surname><given-names>M.-B.</given-names></name><name name-style="western"><surname>Sulaiman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Staatz</surname><given-names>C.E.</given-names></name></person-group><article-title>Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1128/AAC.01543-15</pub-id><pub-id pub-id-type="pmid">26482304</pub-id><pub-id pub-id-type="pmcid">PMC4704176</pub-id></element-citation></ref><ref id="B74-antibiotics-13-00801"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Louart</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saissi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lefrant</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: Comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>71</volume><fpage>464</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv349</pub-id><pub-id pub-id-type="pmid">26538503</pub-id></element-citation></ref><ref id="B75-antibiotics-13-00801"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cotta</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lugano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Della Rocca</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name></person-group><article-title>Does Critical Illness Change Levofloxacin Pharmacokinetics?</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>1459</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1128/AAC.02610-15</pub-id><pub-id pub-id-type="pmid">26666946</pub-id><pub-id pub-id-type="pmcid">PMC4775952</pub-id></element-citation></ref><ref id="B76-antibiotics-13-00801"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulldemolins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mart&#237;n-Loeches</surname><given-names>I.</given-names></name><name name-style="western"><surname>Llaurad&#243;-Serra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vaquer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pontes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soy</surname><given-names>D.</given-names></name></person-group><article-title>Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: Effect of type of dialysis membrane on dosing requirements</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>1651</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv503</pub-id><pub-id pub-id-type="pmid">26869692</pub-id></element-citation></ref><ref id="B77-antibiotics-13-00801"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Louart</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lefrant</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>1643</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw043</pub-id><pub-id pub-id-type="pmid">26957490</pub-id></element-citation></ref><ref id="B78-antibiotics-13-00801"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alobaid</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Jarrett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lassig-Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mejia</surname><given-names>J.L.O.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>4577</fpage><lpage>4584</lpage><pub-id pub-id-type="doi">10.1128/AAC.00531-16</pub-id><pub-id pub-id-type="pmid">27185798</pub-id><pub-id pub-id-type="pmcid">PMC4958171</pub-id></element-citation></ref><ref id="B79-antibiotics-13-00801"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taubert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frechen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holdt</surname><given-names>L.-M.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuhr</surname><given-names>U.</given-names></name><name name-style="western"><surname>Zander</surname><given-names>J.</given-names></name></person-group><article-title>Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>5254</fpage><lpage>5261</lpage><pub-id pub-id-type="doi">10.1128/AAC.00356-16</pub-id><pub-id pub-id-type="pmid">27324768</pub-id><pub-id pub-id-type="pmcid">PMC4997846</pub-id></element-citation></ref><ref id="B80-antibiotics-13-00801"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Goud</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gourley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hewagama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krishnaswamy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis</article-title><source>Int. J. Antimicrob. Agents</source><year>2016</year><volume>48</volume><fpage>542</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.08.015</pub-id><pub-id pub-id-type="pmid">27771187</pub-id></element-citation></ref><ref id="B81-antibiotics-13-00801"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blassmann</surname><given-names>U.</given-names></name><name name-style="western"><surname>Roehr</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>O.R.</given-names></name><name name-style="western"><surname>Vetter-Kerkhoff</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W.</given-names></name><name name-style="western"><surname>Briegel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huge</surname><given-names>V.</given-names></name></person-group><article-title>Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: A prospective observational study</article-title><source>Crit. Care</source><year>2016</year><volume>20</volume><fpage>343</fpage><pub-id pub-id-type="doi">10.1186/s13054-016-1523-y</pub-id><pub-id pub-id-type="pmid">27776537</pub-id><pub-id pub-id-type="pmcid">PMC5078935</pub-id></element-citation></ref><ref id="B82-antibiotics-13-00801"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahbar</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Lodise</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lockwood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Patka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rabinovich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Curzio</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chester</surname><given-names>K.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis</article-title><source>Surg. Infect.</source><year>2016</year><volume>17</volume><fpage>675</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1089/sur.2015.113</pub-id><pub-id pub-id-type="pmid">27841954</pub-id></element-citation></ref><ref id="B83-antibiotics-13-00801"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naik</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Roger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Todorovic</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: A randomized controlled trial</article-title><source>Br. J. Anaesth.</source><year>2017</year><volume>118</volume><fpage>876</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1093/bja/aex026</pub-id><pub-id pub-id-type="pmid">28505360</pub-id></element-citation></ref><ref id="B84-antibiotics-13-00801"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Alobaid</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Roger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e00345-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.00345-17</pub-id><pub-id pub-id-type="pmid">28607024</pub-id><pub-id pub-id-type="pmcid">PMC5527570</pub-id></element-citation></ref><ref id="B85-antibiotics-13-00801"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wicha</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>O.R.</given-names></name><name name-style="western"><surname>Roehr</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Pratschke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stockmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alraish</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wuensch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaffarnik</surname><given-names>M.</given-names></name></person-group><article-title>Linezolid in liver failure: Exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study</article-title><source>Int. J. Antimicrob. Agents</source><year>2017</year><volume>50</volume><fpage>557</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.06.023</pub-id><pub-id pub-id-type="pmid">28711678</pub-id></element-citation></ref><ref id="B86-antibiotics-13-00801"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sime</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>U.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Tiong</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peake</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><pub-id pub-id-type="doi">10.1128/AAC.00311-17</pub-id><pub-id pub-id-type="pmid">28807922</pub-id><pub-id pub-id-type="pmcid">PMC5655099</pub-id></element-citation></ref><ref id="B87-antibiotics-13-00801"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sj&#246;vall</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alobaid</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Perner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>A Roberts</surname><given-names>J.</given-names></name></person-group><article-title>Maximally effective dosing regimens of meropenem in patients with septic shock</article-title><source>J. Antimicrob. Chemother.</source><year>2017</year><volume>73</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx330</pub-id><pub-id pub-id-type="pmid">28961812</pub-id></element-citation></ref><ref id="B88-antibiotics-13-00801"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moor</surname><given-names>A.B.-D.</given-names></name><name name-style="western"><surname>Rypulak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Potr&#281;&#263;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Piwowarczyk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Borys</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sysiak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Onichimowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raszewski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Czuczwar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wiczling</surname><given-names>P.</given-names></name></person-group><article-title>Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><pub-id pub-id-type="doi">10.1128/aac.02273-17</pub-id><pub-id pub-id-type="pmcid">PMC5913959</pub-id><pub-id pub-id-type="pmid">29358291</pub-id></element-citation></ref><ref id="B89-antibiotics-13-00801"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braune</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#246;nig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Nierhaus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Baehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kluge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Langebrake</surname><given-names>C.</given-names></name></person-group><article-title>Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: A population pharmacokinetic study</article-title><source>Crit. Care</source><year>2018</year><volume>22</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/s13054-018-1940-1</pub-id><pub-id pub-id-type="pmid">29382394</pub-id><pub-id pub-id-type="pmcid">PMC5791175</pub-id></element-citation></ref><ref id="B90-antibiotics-13-00801"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Prins</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mist&#237;cio</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Nunguiane</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Beir&#227;o</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>A A Math&#244;t</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Hest</surname><given-names>R.M.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: A population pharmacokinetic modelling study</article-title><source>J. Antimicrob. Chemother.</source><year>2018</year><volume>73</volume><fpage>1620</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1093/jac/dky071</pub-id><pub-id pub-id-type="pmid">29522167</pub-id></element-citation></ref><ref id="B91-antibiotics-13-00801"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>&#214;brink-Hansen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thorsted</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bue</surname><given-names>M.</given-names></name><name name-style="western"><surname>T&#248;ttrup</surname><given-names>M.</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Hardlei</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>S&#248;balle</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gjedsted</surname><given-names>J.</given-names></name></person-group><article-title>Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><pub-id pub-id-type="doi">10.1128/AAC.02390-17</pub-id><pub-id pub-id-type="pmcid">PMC5923145</pub-id><pub-id pub-id-type="pmid">29530848</pub-id></element-citation></ref><ref id="B92-antibiotics-13-00801"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soraluce</surname><given-names>A.</given-names></name><name name-style="western"><surname>As&#237;n-Prieto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrasa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maynar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carcelero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Soy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Isla</surname><given-names>A.</given-names></name></person-group><article-title>Population pharmacokinetics of daptomycin in critically ill patients</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>52</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.03.008</pub-id><pub-id pub-id-type="pmid">29572042</pub-id></element-citation></ref><ref id="B93-antibiotics-13-00801"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alobaid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zelenitsky</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hiremath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Watpool</surname><given-names>I.</given-names></name><name name-style="western"><surname>Porteous</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name></person-group><article-title>Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis</article-title><source>Ann. Pharmacother.</source><year>2018</year><volume>52</volume><fpage>965</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1177/1060028018773771</pub-id><pub-id pub-id-type="pmid">29730948</pub-id></element-citation></ref><ref id="B94-antibiotics-13-00801"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goutelle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Que</surname><given-names>Y.-A.</given-names></name><name name-style="western"><surname>Eggimann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pantet</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sadeghipour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Voirol</surname><given-names>P.</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C.</given-names></name></person-group><article-title>Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><pub-id pub-id-type="doi">10.1128/AAC.00505-18</pub-id><pub-id pub-id-type="pmcid">PMC6125536</pub-id><pub-id pub-id-type="pmid">29914948</pub-id></element-citation></ref><ref id="B95-antibiotics-13-00801"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Hewagama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krishnaswamy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Optimised dosing of vancomycin in critically ill Indigenous Australian patients with severe sepsis</article-title><source>Anaesth. Intensive Care</source><year>2018</year><volume>46</volume><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1177/0310057X1804600405</pub-id><pub-id pub-id-type="pmid">29966110</pub-id></element-citation></ref><ref id="B96-antibiotics-13-00801"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Kojiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Won</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Elbarbry</surname><given-names>F.</given-names></name></person-group><article-title>Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2018</year><volume>92</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2018.06.022</pub-id><pub-id pub-id-type="pmid">30025969</pub-id></element-citation></ref><ref id="B97-antibiotics-13-00801"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stein</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Scharmen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kuti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Havlichek</surname><given-names>D.H.</given-names></name></person-group><article-title>Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients</article-title><source>Surg. Infect.</source><year>2019</year><volume>20</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1089/sur.2018.141</pub-id><pub-id pub-id-type="pmid">30351195</pub-id></element-citation></ref><ref id="B98-antibiotics-13-00801"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leuppi-Taegtmeyer</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Decosterd</surname><given-names>L.</given-names></name><name name-style="western"><surname>Osthoff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>N.</given-names></name></person-group><article-title>Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><pub-id pub-id-type="doi">10.1128/AAC.01957-18</pub-id><pub-id pub-id-type="pmid">30478168</pub-id><pub-id pub-id-type="pmcid">PMC6355613</pub-id></element-citation></ref><ref id="B99-antibiotics-13-00801"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sukarnjanaset</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jaruratanasirikul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wattanavijitkul</surname><given-names>T.</given-names></name></person-group><article-title>Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2019</year><volume>46</volume><fpage>251</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1007/s10928-019-09633-8</pub-id><pub-id pub-id-type="pmid">30963365</pub-id></element-citation></ref><ref id="B100-antibiotics-13-00801"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamora</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Roig</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Badosa</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Riera</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>X.L.P.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Bonin</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Quintano</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>E.S.</given-names></name><etal/></person-group><article-title>Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>2979</fpage><lpage>2983</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz299</pub-id><pub-id pub-id-type="pmid">31335959</pub-id></element-citation></ref><ref id="B101-antibiotics-13-00801"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sime</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Lassig-Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><pub-id pub-id-type="doi">10.1128/AAC.01265-19</pub-id><pub-id pub-id-type="pmcid">PMC6761554</pub-id><pub-id pub-id-type="pmid">31358583</pub-id></element-citation></ref><ref id="B102-antibiotics-13-00801"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zelenitsky</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hiremath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Watpool</surname><given-names>I.</given-names></name><name name-style="western"><surname>Porteous</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name></person-group><article-title>Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis</article-title><source>Clin. Pharmacokinet.</source><year>2020</year><volume>59</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1007/s40262-019-00817-6</pub-id><pub-id pub-id-type="pmid">31471789</pub-id></element-citation></ref><ref id="B103-antibiotics-13-00801"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sime</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Lassig-Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>64</volume><pub-id pub-id-type="doi">10.1128/AAC.01655-19</pub-id><pub-id pub-id-type="pmcid">PMC7187594</pub-id><pub-id pub-id-type="pmid">31658965</pub-id></element-citation></ref><ref id="B104-antibiotics-13-00801"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovacevic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miljkovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kovacevic</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dragic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Momcicevic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Avram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vucicevic</surname><given-names>K.</given-names></name></person-group><article-title>Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients</article-title><source>J. Crit. Care</source><year>2019</year><volume>55</volume><fpage>116</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2019.10.012</pub-id><pub-id pub-id-type="pmid">31715528</pub-id></element-citation></ref><ref id="B105-antibiotics-13-00801"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalaria</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heil</surname><given-names>E.L.</given-names></name></person-group><article-title>A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><pub-id pub-id-type="doi">10.1128/AAC.02093-19</pub-id><pub-id pub-id-type="pmid">31871076</pub-id><pub-id pub-id-type="pmcid">PMC7038264</pub-id></element-citation></ref><ref id="B106-antibiotics-13-00801"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masich</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kalaria</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Heil</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Tata</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Claeys</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>M.</given-names></name></person-group><article-title>Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2020</year><volume>40</volume><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1002/phar.2367</pub-id><pub-id pub-id-type="pmid">31957057</pub-id></element-citation></ref><ref id="B107-antibiotics-13-00801"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okkels</surname><given-names>A.S.L.</given-names></name><name name-style="western"><surname>Hanberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thorsted</surname><given-names>A.</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>&#214;brink-Hansen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>S.</given-names></name></person-group><article-title>Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>92</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.01.010</pub-id><pub-id pub-id-type="pmid">31978581</pub-id></element-citation></ref><ref id="B108-antibiotics-13-00801"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niibe</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>T.-A.</given-names></name><name name-style="western"><surname>Oda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>I.</given-names></name></person-group><article-title>Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients With Acute Kidney Injury Treated With Continuous Hemodiafiltration</article-title><source>Ther. Drug Monit.</source><year>2020</year><volume>42</volume><fpage>588</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000741</pub-id><pub-id pub-id-type="pmid">32049890</pub-id></element-citation></ref><ref id="B109-antibiotics-13-00801"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onichimowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>B&#281;d&#378;kowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zi&#243;&#322;kowski</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jaroszewski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Borys</surname><given-names>M.</given-names></name><name name-style="western"><surname>Czuczwar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wiczling</surname><given-names>P.</given-names></name></person-group><article-title>Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: A prospective observational trial</article-title><source>Pharmacol. Rep.</source><year>2020</year><volume>72</volume><fpage>719</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1007/s43440-020-00104-3</pub-id><pub-id pub-id-type="pmid">32301057</pub-id><pub-id pub-id-type="pmcid">PMC7329797</pub-id></element-citation></ref><ref id="B110-antibiotics-13-00801"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smit</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Schip</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>A van Dongen</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Br&#252;ggemann</surname><given-names>R.J.M.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Knibbe</surname><given-names>C.A.J.</given-names></name></person-group><article-title>Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>3286</fpage><lpage>3292</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa312</pub-id><pub-id pub-id-type="pmid">32785707</pub-id><pub-id pub-id-type="pmcid">PMC7566361</pub-id></element-citation></ref><ref id="B111-antibiotics-13-00801"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blackman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Jarugula</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Chui</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heil</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections</article-title><source>Antimicrob. Agents Chemother.</source><year>2021</year><volume>65</volume><pub-id pub-id-type="doi">10.1128/AAC.01619-20</pub-id><pub-id pub-id-type="pmcid">PMC7848975</pub-id><pub-id pub-id-type="pmid">33257446</pub-id></element-citation></ref><ref id="B112-antibiotics-13-00801"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulldemolins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bastida</surname><given-names>C.</given-names></name><name name-style="western"><surname>Llaurad&#243;-Serra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Badia</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mart&#237;n-Loeches</surname><given-names>I.</given-names></name><name name-style="western"><surname>Soy</surname><given-names>D.</given-names></name></person-group><article-title>Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2021</year><volume>77</volume><fpage>1169</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1007/s00228-021-03100-5</pub-id><pub-id pub-id-type="pmid">33559708</pub-id></element-citation></ref><ref id="B113-antibiotics-13-00801"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study</article-title><source>Drug Des. Dev. Ther.</source><year>2021</year><volume>ume 15</volume><fpage>2129</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S303497</pub-id><pub-id pub-id-type="pmcid">PMC8142937</pub-id><pub-id pub-id-type="pmid">34040351</pub-id></element-citation></ref><ref id="B114-antibiotics-13-00801"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Winter</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Hest</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dreesen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Annaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wauters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meersseman</surname><given-names>W.</given-names></name><name name-style="western"><surname>Eede</surname><given-names>N.V.D.</given-names></name><name name-style="western"><surname>Desmet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verelst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanbrabant</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>2021</year><volume>46</volume><fpage>653</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1007/s13318-021-00698-w</pub-id><pub-id pub-id-type="pmid">34297338</pub-id></element-citation></ref><ref id="B115-antibiotics-13-00801"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>V.</given-names></name><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>F.</given-names></name><name name-style="western"><surname>Buscher</surname><given-names>H.</given-names></name><name name-style="western"><surname>Corley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Levkovich</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Pellegrino</surname><given-names>V.</given-names></name><name name-style="western"><surname>Que</surname><given-names>Y.-A.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study)</article-title><source>Int. J. Antimicrob. Agents</source><year>2021</year><volume>58</volume><fpage>106466</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2021.106466</pub-id><pub-id pub-id-type="pmid">34688834</pub-id></element-citation></ref><ref id="B116-antibiotics-13-00801"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.-X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection</article-title><source>J. Pharm. Sci.</source><year>2022</year><volume>111</volume><fpage>1833</fpage><lpage>1842</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2022.01.015</pub-id><pub-id pub-id-type="pmid">35090867</pub-id></element-citation></ref><ref id="B117-antibiotics-13-00801"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dreesen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gijsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elkayal</surname><given-names>O.</given-names></name><name name-style="western"><surname>Annaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Debaveye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wauters</surname><given-names>J.</given-names></name><name name-style="western"><surname>O Karlsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spriet</surname><given-names>I.</given-names></name></person-group><article-title>Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia</article-title><source>J. Antimicrob. Chemother.</source><year>2022</year><volume>77</volume><fpage>2479</fpage><lpage>2488</lpage><pub-id pub-id-type="doi">10.1093/jac/dkac209</pub-id><pub-id pub-id-type="pmid">35815604</pub-id></element-citation></ref><ref id="B118-antibiotics-13-00801"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meenks</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>le Noble</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Foudraine</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>F.</given-names></name><name name-style="western"><surname>Neef</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>P.K.</given-names></name></person-group><article-title>Population pharmacokinetics of unbound ceftriaxone in a critically ill population</article-title><source>Int. J. Clin. Pharmacol. Ther.</source><year>2022</year><volume>60</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.5414/CP204181</pub-id><pub-id pub-id-type="pmid">35861497</pub-id></element-citation></ref><ref id="B119-antibiotics-13-00801"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshaer</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maranchick</surname><given-names>N.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gramss</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burgmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al Jalali</surname><given-names>V.</given-names></name><name name-style="western"><surname>W&#246;lfl-Duchek</surname><given-names>M.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Poschner</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue</article-title><source>Antimicrob. Agents Chemother.</source><year>2022</year><volume>66</volume><fpage>e0043822</fpage><pub-id pub-id-type="doi">10.1128/aac.00438-22</pub-id><pub-id pub-id-type="pmid">35862739</pub-id><pub-id pub-id-type="pmcid">PMC9380529</pub-id></element-citation></ref><ref id="B120-antibiotics-13-00801"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heffernan</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Cotta</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Livermore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Joynt</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: A Prospective Two-Center Study</article-title><source>Antimicrob. Agents Chemother.</source><year>2022</year><volume>66</volume><fpage>e0014222</fpage><pub-id pub-id-type="doi">10.1128/aac.00142-22</pub-id><pub-id pub-id-type="pmid">35862757</pub-id><pub-id pub-id-type="pmcid">PMC9380572</pub-id></element-citation></ref><ref id="B121-antibiotics-13-00801"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukumoto</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Ohbayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kohyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tamatsukuri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kotani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sagara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dohi</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis</article-title><source>Ther. Drug Monit.</source><year>2022</year><volume>45</volume><fpage>392</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000001040</pub-id><pub-id pub-id-type="pmcid">PMC10168112</pub-id><pub-id pub-id-type="pmid">36253888</pub-id></element-citation></ref><ref id="B122-antibiotics-13-00801"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meenks</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Punt</surname><given-names>N.</given-names></name><name name-style="western"><surname>le Noble</surname><given-names>J.L.M.L.</given-names></name><name name-style="western"><surname>Foudraine</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Neef</surname><given-names>K.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>P.K.C.</given-names></name></person-group><article-title>Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: A multicenter study</article-title><source>Crit. Care</source><year>2023</year><volume>27</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.1186/s13054-023-04353-5</pub-id><pub-id pub-id-type="pmid">36869388</pub-id><pub-id pub-id-type="pmcid">PMC9982780</pub-id></element-citation></ref><ref id="B123-antibiotics-13-00801"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: A real-world prospective study</article-title><source>Crit. Care</source><year>2023</year><volume>27</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/s13054-023-04448-z</pub-id><pub-id pub-id-type="pmid">37106370</pub-id><pub-id pub-id-type="pmcid">PMC10142183</pub-id></element-citation></ref><ref id="B124-antibiotics-13-00801"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type</article-title><source>Drug Des. Dev. Ther.</source><year>2023</year><volume>ume 17</volume><fpage>2259</fpage><lpage>2271</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S413662</pub-id><pub-id pub-id-type="pmcid">PMC10404122</pub-id><pub-id pub-id-type="pmid">37546521</pub-id></element-citation></ref><ref id="B125-antibiotics-13-00801"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barreto</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rule</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Mara</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Meade</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jannetto</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Athreya</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>M.H.</given-names></name><collab>for the BLOOM Study Group</collab></person-group><article-title>Population pharmacokinetic model of cefepime for critically ill adults: A comparative assessment of eGFR equations</article-title><source>Antimicrob. Agents Chemother.</source><year>2023</year><volume>67</volume><fpage>e0081023</fpage><pub-id pub-id-type="doi">10.1128/aac.00810-23</pub-id><pub-id pub-id-type="pmid">37882514</pub-id><pub-id pub-id-type="pmcid">PMC10648925</pub-id></element-citation></ref><ref id="B126-antibiotics-13-00801"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Facca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frame</surname><given-names>B.</given-names></name><name name-style="western"><surname>Triesenberg</surname><given-names>S.</given-names></name></person-group><article-title>Population Pharmacokinetics of Ceftizoxime Administered by Continuous Infusion in Clinically Ill Adult Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>1998</year><volume>42</volume><fpage>1783</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.7.1783</pub-id><pub-id pub-id-type="pmid">9661021</pub-id><pub-id pub-id-type="pmcid">PMC105683</pub-id></element-citation></ref><ref id="B127-antibiotics-13-00801"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frame</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Facca</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Triesenberg</surname><given-names>S.N.</given-names></name></person-group><article-title>Population Pharmacokinetics of Continuous Infusion Ceftazidime</article-title><source>Clin. Pharmacokinet.</source><year>1999</year><volume>37</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.2165/00003088-199937040-00005</pub-id><pub-id pub-id-type="pmid">10554049</pub-id></element-citation></ref><ref id="B128-antibiotics-13-00801"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dailly</surname><given-names>E.</given-names></name><name name-style="western"><surname>Arnould</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fraissinet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Naux</surname><given-names>E.</given-names></name><name name-style="western"><surname>de la Bourali&#232;re</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Bouqui&#233;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deslandes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jolliet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Le Floch</surname><given-names>R.</given-names></name></person-group><article-title>Pharmacokinetics of ertapenem in burns patients</article-title><source>Int. J. Antimicrob. Agents</source><year>2013</year><volume>42</volume><fpage>48</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.02.021</pub-id><pub-id pub-id-type="pmid">23578794</pub-id></element-citation></ref><ref id="B129-antibiotics-13-00801"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beumier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kabtouri</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hites</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>F.S.</given-names></name></person-group><article-title>A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy</article-title><source>J. Antimicrob. Chemother.</source><year>2013</year><volume>68</volume><fpage>2859</fpage><lpage>2865</lpage><pub-id pub-id-type="doi">10.1093/jac/dkt261</pub-id><pub-id pub-id-type="pmid">23800905</pub-id></element-citation></ref><ref id="B130-antibiotics-13-00801"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;brink-Hansen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Juul</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Storgaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Hardlei</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Brock</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kreilgaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gjedsted</surname><given-names>J.</given-names></name></person-group><article-title>Population Pharmacokinetics of Piperacillin in the Early Phase of Septic Shock: Does Standard Dosing Result in Therapeutic Plasma Concentrations?</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>7018</fpage><lpage>7026</lpage><pub-id pub-id-type="doi">10.1128/AAC.01347-15</pub-id><pub-id pub-id-type="pmid">26349823</pub-id><pub-id pub-id-type="pmcid">PMC4604352</pub-id></element-citation></ref><ref id="B131-antibiotics-13-00801"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>W.-W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>R.-F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.-Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.-F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.-L.</given-names></name></person-group><article-title>Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2015</year><volume>72</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s00228-015-1952-6</pub-id><pub-id pub-id-type="pmid">26423622</pub-id></element-citation></ref><ref id="B132-antibiotics-13-00801"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ide</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takesue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ikawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishi</surname><given-names>S.</given-names></name></person-group><article-title>Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>51</volume><fpage>745</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.01.021</pub-id><pub-id pub-id-type="pmid">29425834</pub-id></element-citation></ref><ref id="B133-antibiotics-13-00801"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Min</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M.J.</given-names></name></person-group><article-title>Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><pub-id pub-id-type="doi">10.1128/AAC.00249-20</pub-id><pub-id pub-id-type="pmcid">PMC7179593</pub-id><pub-id pub-id-type="pmid">32122899</pub-id></element-citation></ref><ref id="B134-antibiotics-13-00801"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grensemann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Busse</surname><given-names>D.</given-names></name><name name-style="western"><surname>K&#246;nig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roedl</surname><given-names>K.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jarczak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iwersen-Bergmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manthey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kluge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: An observational study</article-title><source>Ann. Intensive Care</source><year>2020</year><volume>10</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s13613-020-00666-8</pub-id><pub-id pub-id-type="pmid">32323030</pub-id><pub-id pub-id-type="pmcid">PMC7176801</pub-id></element-citation></ref><ref id="B135-antibiotics-13-00801"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Influence of venovenous extracorporeal membrane oxygenation on pharmacokinetics of vancomycin in lung transplant recipients</article-title><source>J. Clin. Pharm. Ther.</source><year>2020</year><volume>45</volume><fpage>1066</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1111/jcpt.13163</pub-id><pub-id pub-id-type="pmid">32542736</pub-id></element-citation></ref><ref id="B136-antibiotics-13-00801"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>M.</given-names></name><collab>Castellanos-Ortega</collab></person-group><article-title>Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections</article-title><source>SAGE Open Med.</source><year>2020</year><volume>8</volume><pub-id pub-id-type="doi">10.1177/2050312120958897</pub-id><pub-id pub-id-type="pmcid">PMC7506777</pub-id><pub-id pub-id-type="pmid">32999720</pub-id></element-citation></ref><ref id="B137-antibiotics-13-00801"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.-Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.-L.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.-H.</given-names></name></person-group><article-title>Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>2670</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-82312-2</pub-id><pub-id pub-id-type="pmid">33514803</pub-id><pub-id pub-id-type="pmcid">PMC7846798</pub-id></element-citation></ref><ref id="B138-antibiotics-13-00801"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;&#237;ma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Michali&#269;kov&#225;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ry&#353;&#225;nek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cihl&#225;&#345;ov&#225;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kucha&#345;</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#382;i&#269;a&#345;ov&#225;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Berou&#353;ek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hartinger</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Vymazal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Slana&#345;</surname><given-names>O.</given-names></name></person-group><article-title>No Time Dependence of Ciprofloxacin Pharmacokinetics in Critically Ill Adults: Comparison of Individual and Population Analyses</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1156</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13081156</pub-id><pub-id pub-id-type="pmid">34452118</pub-id><pub-id pub-id-type="pmcid">PMC8402031</pub-id></element-citation></ref><ref id="B139-antibiotics-13-00801"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.-K.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>D.-X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sandaradura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name></person-group><article-title>Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients</article-title><source>Infect. Dis. Ther.</source><year>2021</year><volume>11</volume><fpage>201</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1007/s40121-021-00551-2</pub-id><pub-id pub-id-type="pmid">34748194</pub-id><pub-id pub-id-type="pmcid">PMC8847520</pub-id></element-citation></ref><ref id="B140-antibiotics-13-00801"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsultan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dasuqi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Aljamaan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Omran</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Syed</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>AlJaloud</surname><given-names>T.</given-names></name><name name-style="western"><surname>AlAhmadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alqahtani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamad</surname><given-names>M.A.</given-names></name></person-group><article-title>Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia</article-title><source>Saudi Pharm. J.</source><year>2021</year><volume>29</volume><fpage>1272</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2021.09.017</pub-id><pub-id pub-id-type="pmid">34819789</pub-id><pub-id pub-id-type="pmcid">PMC8596159</pub-id></element-citation></ref><ref id="B141-antibiotics-13-00801"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Q.</given-names></name></person-group><article-title>Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>1392</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10111392</pub-id><pub-id pub-id-type="pmid">34827330</pub-id><pub-id pub-id-type="pmcid">PMC8614878</pub-id></element-citation></ref><ref id="B142-antibiotics-13-00801"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Busse</surname><given-names>D.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Petroff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huisinga</surname><given-names>W.</given-names></name><name name-style="western"><surname>Michelet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wrigge</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients</article-title><source>Clin. Pharmacokinet.</source><year>2021</year><volume>61</volume><fpage>655</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1007/s40262-021-01070-6</pub-id><pub-id pub-id-type="pmid">34894344</pub-id><pub-id pub-id-type="pmcid">PMC9095536</pub-id></element-citation></ref><ref id="B143-antibiotics-13-00801"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farkas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oikonomou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ghanbar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villasurda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sassine</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ranganathan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Population Pharmacokinetics of Intraperitoneal Gentamicin and the Impact of Varying Dwell Times on Pharmacodynamic Target Attainment in Patients with Acute Peritonitis Undergoing Peritoneal Dialysis</article-title><source>Antimicrob. Agents Chemother.</source><year>2022</year><volume>66</volume><fpage>e0167921</fpage><pub-id pub-id-type="doi">10.1128/aac.01679-21</pub-id><pub-id pub-id-type="pmid">34902267</pub-id><pub-id pub-id-type="pmcid">PMC8846465</pub-id></element-citation></ref><ref id="B144-antibiotics-13-00801"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hahn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Min</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Wi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M.J.</given-names></name></person-group><article-title>Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy</article-title><source>Microbiol. Spectr.</source><year>2021</year><volume>9</volume><elocation-id>e0063321</elocation-id><pub-id pub-id-type="doi">10.1128/Spectrum.00633-21</pub-id><pub-id pub-id-type="pmid">34937189</pub-id><pub-id pub-id-type="pmcid">PMC8694146</pub-id></element-citation></ref><ref id="B145-antibiotics-13-00801"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gijsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elkayal</surname><given-names>O.</given-names></name><name name-style="western"><surname>Annaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Daele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meersseman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Debaveye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wauters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dreesen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spriet</surname><given-names>I.</given-names></name></person-group><article-title>Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function</article-title><source>Infect. Drug Resist.</source><year>2022</year><volume>15</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.2147/IDR.S343264</pub-id><pub-id pub-id-type="pmid">35035223</pub-id><pub-id pub-id-type="pmcid">PMC8754504</pub-id></element-citation></ref><ref id="B146-antibiotics-13-00801"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pressiat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kudela</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Roux</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Khoudour</surname><given-names>N.</given-names></name><name name-style="western"><surname>Alessandri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Haouache</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vodovar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Woerther</surname><given-names>P.-L.</given-names></name><name name-style="western"><surname>Hutin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghaleh</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>289</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14020289</pub-id><pub-id pub-id-type="pmid">35214022</pub-id><pub-id pub-id-type="pmcid">PMC8879580</pub-id></element-citation></ref><ref id="B147-antibiotics-13-00801"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alihodzic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>O.R.</given-names></name><name name-style="western"><surname>K&#246;nig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jarczak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kluge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Langebrake</surname><given-names>C.</given-names></name></person-group><article-title>Ciprofloxacin in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): A Population Pharmacokinetic Study</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>965</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14050965</pub-id><pub-id pub-id-type="pmid">35631551</pub-id><pub-id pub-id-type="pmcid">PMC9145815</pub-id></element-citation></ref><ref id="B148-antibiotics-13-00801"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;&#237;ma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bobek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cihl&#225;&#345;ov&#225;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ry&#353;&#225;nek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rou&#353;arov&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berou&#353;ek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kucha&#345;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vymazal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Slana&#345;</surname><given-names>O.</given-names></name></person-group><article-title>Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1627</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14081627</pub-id><pub-id pub-id-type="pmid">36015253</pub-id><pub-id pub-id-type="pmcid">PMC9413960</pub-id></element-citation></ref><ref id="B149-antibiotics-13-00801"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Min</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Wi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M.J.</given-names></name></person-group><article-title>Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>6621</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11226621</pub-id><pub-id pub-id-type="pmid">36431106</pub-id><pub-id pub-id-type="pmcid">PMC9693387</pub-id></element-citation></ref><ref id="B150-antibiotics-13-00801"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>G.</given-names></name><name name-style="western"><surname>Creech</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nation</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nalbant</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jimenez-Truque</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fissell</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rolsma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.C.</given-names></name><etal/></person-group><article-title>Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis</article-title><source>Antimicrob. Agents Chemother.</source><year>2023</year><volume>67</volume><fpage>e0131222</fpage><pub-id pub-id-type="doi">10.1128/aac.01312-22</pub-id><pub-id pub-id-type="pmid">36622154</pub-id><pub-id pub-id-type="pmcid">PMC9872596</pub-id></element-citation></ref><ref id="B151-antibiotics-13-00801"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>M.</given-names></name></person-group><article-title>Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients</article-title><source>Eur. J. Hosp. Pharm.</source><year>2023</year><pub-id pub-id-type="doi">10.1136/ejhpharm-2022-003403</pub-id><pub-id pub-id-type="pmcid">PMC11347199</pub-id><pub-id pub-id-type="pmid">36948580</pub-id></element-citation></ref><ref id="B152-antibiotics-13-00801"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Casanova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Esteve-Pitarch</surname><given-names>E.</given-names></name><name name-style="western"><surname>Colom-Codina</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gumucio-Sanguino</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Cobo-Sacrist&#225;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maisterra-Santos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sabater-Riera</surname><given-names>J.</given-names></name><name name-style="western"><surname>P&#233;rez-Fernandez</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Rigo-Bonnin</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients</article-title><source>Antibiotics</source><year>2023</year><volume>12</volume><elocation-id>531</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12030531</pub-id><pub-id pub-id-type="pmid">36978398</pub-id><pub-id pub-id-type="pmcid">PMC10044067</pub-id></element-citation></ref><ref id="B153-antibiotics-13-00801"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>G.</given-names></name><name name-style="western"><surname>Creech</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nation</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nalbant</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jimenez-Truque</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fissell</surname><given-names>W.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Fishbane</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>78</volume><fpage>1460</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1093/jac/dkad106</pub-id><pub-id pub-id-type="pmid">37071586</pub-id><pub-id pub-id-type="pmcid">PMC10474939</pub-id></element-citation></ref><ref id="B154-antibiotics-13-00801"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuhr</surname><given-names>U.</given-names></name><name name-style="western"><surname>Jaehde</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liebchen</surname><given-names>U.</given-names></name><name name-style="western"><surname>B&#252;sker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zander</surname><given-names>J.</given-names></name><name name-style="western"><surname>Flury</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Taubert</surname><given-names>M.</given-names></name></person-group><article-title>Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2023</year><volume>67</volume><fpage>e0030923</fpage><pub-id pub-id-type="doi">10.1128/aac.00309-23</pub-id><pub-id pub-id-type="pmid">37366614</pub-id><pub-id pub-id-type="pmcid">PMC10353438</pub-id></element-citation></ref><ref id="B155-antibiotics-13-00801"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Minichmayr</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huisinga</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zander</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C.</given-names></name></person-group><article-title>Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis</article-title><source>Int. J. Antimicrob. Agents</source><year>2019</year><volume>54</volume><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.06.016</pub-id><pub-id pub-id-type="pmid">31229669</pub-id></element-citation></ref><ref id="B156-antibiotics-13-00801"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soraluce</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrasa</surname><given-names>H.</given-names></name><name name-style="western"><surname>As&#237;n-Prieto</surname><given-names>E.</given-names></name><name name-style="western"><surname>S&#225;nchez-Izquierdo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maynar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Isla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A.</given-names></name></person-group><article-title>Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12010054</pub-id><pub-id pub-id-type="pmid">31936614</pub-id><pub-id pub-id-type="pmcid">PMC7023070</pub-id></element-citation></ref><ref id="B157-antibiotics-13-00801"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>W.-B.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>No</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><pub-id pub-id-type="doi">10.3389/fphar.2021.768912</pub-id><pub-id pub-id-type="pmid">34790131</pub-id><pub-id pub-id-type="pmcid">PMC8591204</pub-id></element-citation></ref><ref id="B158-antibiotics-13-00801"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dedkaew</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cressey</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Punyawudho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lucksiri</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics of vancomycin in critically ill patients in Thailand</article-title><source>Int. J. Pharm. Pharm. Sci.</source><year>2015</year><volume>7</volume><fpage>232</fpage><lpage>237</lpage></element-citation></ref><ref id="B159-antibiotics-13-00801"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.-H.</given-names></name></person-group><article-title>Population Pharmacokinetics and Monte Carlo Simulation of Cefepime in Critically Ill Patients with Hospital-Acquired/Ventilator-Associated Pneumonia</article-title><source>Infect. Chemother.</source><year>2023</year><volume>55</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.3947/ic.2022.0087</pub-id><pub-id pub-id-type="pmid">36450287</pub-id><pub-id pub-id-type="pmcid">PMC10079447</pub-id></element-citation></ref><ref id="B160-antibiotics-13-00801"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattioli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fucile</surname><given-names>C.</given-names></name><name name-style="western"><surname>Del Bono</surname><given-names>V.</given-names></name><name name-style="western"><surname>Marini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Parisini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Molin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zuccoli</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Milano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Danesi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marchese</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2016</year><volume>72</volume><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1007/s00228-016-2053-x</pub-id><pub-id pub-id-type="pmid">27048201</pub-id></element-citation></ref><ref id="B161-antibiotics-13-00801"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdulla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rogouti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>N.G.M.</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>B.C.M.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.C.P.</given-names></name></person-group><article-title>Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2020</year><volume>76</volume><fpage>957</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1007/s00228-020-02873-5</pub-id><pub-id pub-id-type="pmid">32307575</pub-id><pub-id pub-id-type="pmcid">PMC7306030</pub-id></element-citation></ref><ref id="B162-antibiotics-13-00801"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>V.</given-names></name><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>F.</given-names></name><name name-style="western"><surname>Buscher</surname><given-names>H.</given-names></name><name name-style="western"><surname>Corley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Levkovich</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Pellegrino</surname><given-names>V.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rudham</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study)</article-title><source>Anaesth. Crit. Care Pain Med.</source><year>2022</year><volume>41</volume><fpage>101080</fpage><pub-id pub-id-type="doi">10.1016/j.accpm.2022.101080</pub-id><pub-id pub-id-type="pmid">35472580</pub-id></element-citation></ref><ref id="B163-antibiotics-13-00801"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Troc&#243;niz</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Solin&#237;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maynar</surname><given-names>J.</given-names></name><name name-style="western"><surname>S&#225;nchez-Izquierdo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pedraz</surname><given-names>J.L.</given-names></name></person-group><article-title>Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy</article-title><source>Clin. Pharmacokinet.</source><year>2008</year><volume>47</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.2165/00003088-200847030-00003</pub-id><pub-id pub-id-type="pmid">18307371</pub-id></element-citation></ref><ref id="B164-antibiotics-13-00801"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alobaid</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Jarrett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lassig-Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mejia</surname><given-names>J.L.O.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Roger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Udy</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e01276-16</fpage><pub-id pub-id-type="doi">10.1128/AAC.01276-16</pub-id><pub-id pub-id-type="pmid">28052849</pub-id><pub-id pub-id-type="pmcid">PMC5328553</pub-id></element-citation></ref><ref id="B165-antibiotics-13-00801"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.-H.</given-names></name></person-group><article-title>Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation</article-title><source>J. Antimicrob. Chemother.</source><year>2022</year><volume>77</volume><fpage>1353</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1093/jac/dkac059</pub-id><pub-id pub-id-type="pmid">35224630</pub-id><pub-id pub-id-type="pmcid">PMC9047688</pub-id></element-citation></ref><ref id="B166-antibiotics-13-00801"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ernest</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>D.J.</given-names></name></person-group><article-title>Gentamicin clearance during continuous arteriovenous hemodiafiltration</article-title><source>Crit. Care Med.</source><year>1992</year><volume>20</volume><fpage>586</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1097/00003246-199205000-00007</pub-id><pub-id pub-id-type="pmid">1572182</pub-id></element-citation></ref><ref id="B167-antibiotics-13-00801"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shikuma</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Solem</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Strate</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Cerra</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Zaske</surname><given-names>D.E.</given-names></name></person-group><article-title>Effects of treatment and the metabolic response to injury on drug clearance: A prospective study with piperacillin</article-title><source>Crit Care Med.</source><year>1990</year><volume>18</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1097/00003246-199001000-00010</pub-id><pub-id pub-id-type="pmid">2293966</pub-id></element-citation></ref><ref id="B168-antibiotics-13-00801"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornwell</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Belzberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Berne</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Theodorou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Asensio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Demetriades</surname><given-names>D.</given-names></name></person-group><article-title>Pharmacokinetics of aztreonam in critically ill surgical patients</article-title><source>Am. J. Heal. Pharm.</source><year>1997</year><volume>54</volume><fpage>537</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1093/ajhp/54.5.537</pub-id><pub-id pub-id-type="pmid">9066861</pub-id></element-citation></ref><ref id="B169-antibiotics-13-00801"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giles</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Creed</surname><given-names>G.</given-names></name><name name-style="western"><surname>Beale</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>McLuckie</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration</article-title><source>Crit. Care Med.</source><year>2000</year><volume>28</volume><fpage>632</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1097/00003246-200003000-00005</pub-id><pub-id pub-id-type="pmid">10752806</pub-id></element-citation></ref><ref id="B170-antibiotics-13-00801"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barletta</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Nix</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Nix</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Erstad</surname><given-names>B.L.</given-names></name></person-group><article-title>Population Pharmacokinetics of Aminoglycosides in Critically Ill Trauma Patients on Once-Daily Regimens</article-title><source>J. Trauma: Inj. Infect. Crit. Care</source><year>2000</year><volume>49</volume><fpage>869</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1097/00005373-200011000-00013</pub-id><pub-id pub-id-type="pmid">11086778</pub-id></element-citation></ref><ref id="B171-antibiotics-13-00801"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malone</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>E.</given-names></name><name name-style="western"><surname>Teitelbaum</surname><given-names>I.</given-names></name></person-group><article-title>Pharmacokinetics of Cefepime during Continuous Renal Replacement Therapy in Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2001</year><volume>45</volume><fpage>3148</fpage><lpage>3155</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.11.3148-3155.2001</pub-id><pub-id pub-id-type="pmid">11600370</pub-id><pub-id pub-id-type="pmcid">PMC90796</pub-id></element-citation></ref><ref id="B172-antibiotics-13-00801"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traunm&#252;ller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schenk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mittermeyer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thalhammer-Scherrer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ratheiser</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thalhammer</surname><given-names>F.</given-names></name></person-group><article-title>Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients</article-title><source>J. Antimicrob. Chemother.</source><year>2002</year><volume>49</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1093/jac/49.1.129</pub-id><pub-id pub-id-type="pmid">11751776</pub-id></element-citation></ref><ref id="B173-antibiotics-13-00801"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>L.</given-names></name><name name-style="western"><surname>Morimatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R.</given-names></name></person-group><article-title>Clearance of vancomycin during high-volume haemofiltration: Impact of pre-dilution</article-title><source>Intensive Care Med.</source><year>2002</year><volume>28</volume><fpage>1664</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1007/s00134-002-1495-z</pub-id><pub-id pub-id-type="pmid">12583375</pub-id></element-citation></ref><ref id="B174-antibiotics-13-00801"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiaccadori</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maggiore</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rotelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giacosa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parenti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Picetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sagripanti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Andreoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cabassi</surname><given-names>A.</given-names></name></person-group><article-title>Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure</article-title><source>Crit. Care Med.</source><year>2004</year><volume>32</volume><fpage>2437</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000147687.06808.92</pub-id><pub-id pub-id-type="pmid">15599148</pub-id></element-citation></ref><ref id="B175-antibiotics-13-00801"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kornek</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Nikfardjam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karth</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Locker</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Jaeger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Thalhammer</surname><given-names>F.</given-names></name></person-group><article-title>Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration</article-title><source>J. Antimicrob. Chemother.</source><year>2005</year><volume>56</volume><fpage>172</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1093/jac/dki133</pub-id><pub-id pub-id-type="pmid">15905303</pub-id></element-citation></ref><ref id="B176-antibiotics-13-00801"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fish</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Teitelbaum</surname><given-names>I.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>E.</given-names></name></person-group><article-title>Pharmacokinetics and Pharmacodynamics of Imipenem during Continuous Renal Replacement Therapy in Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2005</year><volume>49</volume><fpage>2421</fpage><lpage>2428</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.6.2421-2428.2005</pub-id><pub-id pub-id-type="pmid">15917542</pub-id><pub-id pub-id-type="pmcid">PMC1140495</pub-id></element-citation></ref><ref id="B177-antibiotics-13-00801"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kielstein</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Czock</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sch&#246;pke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hafer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bode-B&#246;ger</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kuse</surname><given-names>E.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fliser</surname><given-names>D.</given-names></name></person-group><article-title>Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis*</article-title><source>Crit. Care Med.</source><year>2006</year><volume>34</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000190243.88133.3F</pub-id><pub-id pub-id-type="pmid">16374156</pub-id></element-citation></ref><ref id="B178-antibiotics-13-00801"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klansuwan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ratanajamit</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kasiwong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wangsiripaisan</surname><given-names>A.</given-names></name></person-group><article-title>Clearance of vancomycin during high-efficiency hemodialysis</article-title><source>J. Med. Assoc. Thail.</source><year>2006</year><volume>89</volume><fpage>986</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">16881431</pub-id></element-citation></ref><ref id="B179-antibiotics-13-00801"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bracco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Landry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Eggimann</surname><given-names>P.</given-names></name></person-group><article-title>Pharmacokinetic variability of extended interval tobramycin in burn patients</article-title><source>Burns</source><year>2008</year><volume>34</volume><fpage>791</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/j.burns.2007.11.003</pub-id><pub-id pub-id-type="pmid">18395988</pub-id></element-citation></ref><ref id="B180-antibiotics-13-00801"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkhardt</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hafer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Langhoff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaever</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haller</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fliser</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kielstein</surname><given-names>J.T.</given-names></name></person-group><article-title>Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis</article-title><source>Nephrol. Dial. Transplant.</source><year>2008</year><volume>24</volume><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfn472</pub-id><pub-id pub-id-type="pmid">18723863</pub-id></element-citation></ref><ref id="B181-antibiotics-13-00801"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golestaneh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gofran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mokrzycki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Removal of vancomycin in sustained low-efficiency dialysis (SLED): A need for better surveillance and dosing</article-title><source>Clin. Nephrol.</source><year>2009</year><volume>72</volume><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.5414/CNP72286</pub-id><pub-id pub-id-type="pmid">19825334</pub-id></element-citation></ref><ref id="B182-antibiotics-13-00801"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deshpande</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gofran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murea</surname><given-names>M.</given-names></name><name name-style="western"><surname>Golestaneh</surname><given-names>L.</given-names></name></person-group><article-title>Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED)</article-title><source>Nephrol. Dial. Transplant.</source><year>2010</year><volume>25</volume><fpage>2632</fpage><lpage>2636</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq090</pub-id><pub-id pub-id-type="pmid">20181801</pub-id></element-citation></ref><ref id="B183-antibiotics-13-00801"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilgrami</surname><given-names>I.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goldrick</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name></person-group><article-title>Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>2974</fpage><lpage>2978</lpage><pub-id pub-id-type="doi">10.1128/AAC.01582-09</pub-id><pub-id pub-id-type="pmid">20479205</pub-id><pub-id pub-id-type="pmcid">PMC2897321</pub-id></element-citation></ref><ref id="B184-antibiotics-13-00801"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seyler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Macours</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F.</given-names></name></person-group><article-title>Recommended &#946;-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy</article-title><source>Crit. Care</source><year>2011</year><volume>15</volume><fpage>R137</fpage><pub-id pub-id-type="doi">10.1186/cc10257</pub-id><pub-id pub-id-type="pmid">21649882</pub-id><pub-id pub-id-type="pmcid">PMC3219006</pub-id></element-citation></ref><ref id="B185-antibiotics-13-00801"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baptista</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Pimentel</surname><given-names>J.M.</given-names></name></person-group><article-title>Augmented renal clearance in septic patients and implications for vancomycin optimisation</article-title><source>Int. J. Antimicrob. Agents</source><year>2012</year><volume>39</volume><fpage>420</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2011.12.011</pub-id><pub-id pub-id-type="pmid">22386742</pub-id></element-citation></ref><ref id="B186-antibiotics-13-00801"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R.</given-names></name></person-group><article-title>Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy</article-title><source>Crit. Care Med.</source><year>2012</year><volume>40</volume><fpage>1523</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318241e553</pub-id><pub-id pub-id-type="pmid">22511133</pub-id></element-citation></ref><ref id="B187-antibiotics-13-00801"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petejova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martinek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zahalkova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duricova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brozmannova</surname><given-names>H.</given-names></name><name name-style="western"><surname>Urbanek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Grundmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plasek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kacirova</surname><given-names>I.</given-names></name></person-group><article-title>Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients</article-title><source>Biomed. Pap.</source><year>2014</year><volume>158</volume><fpage>065</fpage><lpage>072</lpage><pub-id pub-id-type="doi">10.5507/bp.2012.092</pub-id><pub-id pub-id-type="pmid">23132513</pub-id></element-citation></ref><ref id="B188-antibiotics-13-00801"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;arcy</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gowing</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>I Corrigan</surname><given-names>O.</given-names></name></person-group><article-title>An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration</article-title><source>BMC Pharmacol. Toxicol.</source><year>2012</year><volume>13</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/2050-6511-13-14</pub-id><pub-id pub-id-type="pmid">23136834</pub-id><pub-id pub-id-type="pmcid">PMC3517742</pub-id></element-citation></ref><ref id="B189-antibiotics-13-00801"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schw&#246;rer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoppe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Streit</surname><given-names>F.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wachter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oellerich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walson</surname><given-names>P.D.</given-names></name></person-group><article-title>Pharmacokinetics of Meropenem in Critically Ill Patients With Severe Infections</article-title><source>Ther. Drug Monit.</source><year>2013</year><volume>35</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e31827d496c</pub-id><pub-id pub-id-type="pmid">23318279</pub-id></element-citation></ref><ref id="B190-antibiotics-13-00801"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adnan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jarrett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Udy</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains</article-title><source>Int. J. Antimicrob. Agents</source><year>2013</year><volume>42</volume><fpage>90</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.02.023</pub-id><pub-id pub-id-type="pmid">23590897</pub-id></element-citation></ref><ref id="B191-antibiotics-13-00801"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carrette</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Stove</surname><given-names>V.</given-names></name><name name-style="western"><surname>Verstraete</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoste</surname><given-names>E.</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Decruyenaere</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Meropenem and piperacillin/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?</article-title><source>Crit. Care</source><year>2013</year><volume>17</volume><fpage>R84</fpage><pub-id pub-id-type="doi">10.1186/cc12705</pub-id><pub-id pub-id-type="pmid">23642005</pub-id><pub-id pub-id-type="pmcid">PMC4056350</pub-id></element-citation></ref><ref id="B192-antibiotics-13-00801"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sturm</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rafferty</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Toschlog</surname><given-names>E.</given-names></name><name name-style="western"><surname>Newell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Waibel</surname><given-names>B.</given-names></name></person-group><article-title>Pharmacokinetic Analysis of Piperacillin Administered with Tazobactam in Critically Ill, Morbidly Obese Surgical Patients</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2013</year><volume>34</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1002/phar.1324</pub-id><pub-id pub-id-type="pmid">23864417</pub-id></element-citation></ref><ref id="B193-antibiotics-13-00801"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carrette</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stove</surname><given-names>V.</given-names></name><name name-style="western"><surname>Verstraete</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.J.</given-names></name></person-group><article-title>Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course</article-title><source>Int. J. Antimicrob. Agents</source><year>2014</year><volume>43</volume><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.01.028</pub-id><pub-id pub-id-type="pmid">24685990</pub-id></element-citation></ref><ref id="B194-antibiotics-13-00801"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Von Dach</surname><given-names>E.</given-names></name><name name-style="western"><surname>Renzoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Affaticati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daali</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pugin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Karmime</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study</article-title><source>Int. J. Antimicrob. Agents</source><year>2015</year><volume>45</volume><fpage>385</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.12.017</pub-id><pub-id pub-id-type="pmid">25656151</pub-id></element-citation></ref><ref id="B195-antibiotics-13-00801"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sime</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Tiong</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peake</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>U.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>70</volume><fpage>2369</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv123</pub-id><pub-id pub-id-type="pmid">25953805</pub-id></element-citation></ref><ref id="B196-antibiotics-13-00801"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awissi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beauchamp</surname><given-names>A.</given-names></name><name name-style="western"><surname>H&#233;bert</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lavigne</surname><given-names>V.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Lebrun</surname><given-names>G.</given-names></name><name name-style="western"><surname>Savoie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fagnan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amyot</surname><given-names>J.</given-names></name><name name-style="western"><surname>T&#233;treault</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of an Extended 4-hour Infusion of Piperacillin-Tazobactam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2015</year><volume>35</volume><fpage>600</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1002/phar.1604</pub-id><pub-id pub-id-type="pmid">26095008</pub-id></element-citation></ref><ref id="B197-antibiotics-13-00801"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cassetta</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Tofani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valente</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chelazzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Falsini</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Gaudio</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ronco</surname><given-names>C.</given-names></name><name name-style="western"><surname>Adembri</surname><given-names>C.</given-names></name></person-group><article-title>Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients</article-title><source>Int. J. Antimicrob. Agents</source><year>2015</year><volume>46</volume><fpage>465</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2015.06.015</pub-id><pub-id pub-id-type="pmid">26315198</pub-id></element-citation></ref><ref id="B198-antibiotics-13-00801"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J.</given-names></name></person-group><article-title>Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study</article-title><source>PLOS ONE</source><year>2016</year><volume>11</volume><fpage>e0153927</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0153927</pub-id><pub-id pub-id-type="pmid">27093294</pub-id><pub-id pub-id-type="pmcid">PMC4836878</pub-id></element-citation></ref><ref id="B199-antibiotics-13-00801"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boucher</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Laizure</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Arnold-Ross</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Hickerson</surname><given-names>W.L.</given-names></name></person-group><article-title>Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2016</year><volume>36</volume><fpage>1229</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1002/phar.1866</pub-id><pub-id pub-id-type="pmid">27862103</pub-id></element-citation></ref><ref id="B200-antibiotics-13-00801"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mahul</surname><given-names>M.</given-names></name><name name-style="western"><surname>Breilh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Legeron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Signe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jean-Pierre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uhlemann</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Molinari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jaber</surname><given-names>S.</given-names></name></person-group><article-title>Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under&#8211; and Overdosing*</article-title><source>Crit. Care Med.</source><year>2017</year><volume>45</volume><fpage>e470</fpage><lpage>e478</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000002287</pub-id><pub-id pub-id-type="pmid">28240688</pub-id></element-citation></ref><ref id="B201-antibiotics-13-00801"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cotta</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lefrant</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients</article-title><source>Int. J. Antimicrob. Agents</source><year>2017</year><volume>50</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.03.018</pub-id><pub-id pub-id-type="pmid">28689876</pub-id></element-citation></ref><ref id="B202-antibiotics-13-00801"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carri&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petit</surname><given-names>L.</given-names></name><name name-style="western"><surname>D'Houdain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sauvage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cottenceau</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lafitte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foumenteze</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hisz</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Menu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Legeron</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of &#946;-lactams administered by continuous infusion: A prospective observational study</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>51</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.11.013</pub-id><pub-id pub-id-type="pmid">29180280</pub-id></element-citation></ref><ref id="B203-antibiotics-13-00801"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz-Ramos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martin-Cerezula</surname><given-names>M.</given-names></name><name name-style="western"><surname>Broch</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Marqu&#233;s</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Poveda</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Castellanos-Ortega</surname></name><name name-style="western"><surname>Ram&#237;rez</surname><given-names>P.</given-names></name></person-group><article-title>Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients</article-title><source>Blood Purif.</source><year>2017</year><volume>45</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1159/000478969</pub-id><pub-id pub-id-type="pmid">29232669</pub-id></element-citation></ref><ref id="B204-antibiotics-13-00801"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eggimann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pantet</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Dupuis-Lozeron</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pannatier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadeghipour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Voirol</surname><given-names>P.</given-names></name><name name-style="western"><surname>Que</surname><given-names>Y.-A.</given-names></name></person-group><article-title>Impact of Real-Time Therapeutic Drug Monitoring on the Prescription of Antibiotics in Burn Patients Requiring Admission to the Intensive Care Unit</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><pub-id pub-id-type="doi">10.1128/AAC.01818-17</pub-id><pub-id pub-id-type="pmid">29263079</pub-id><pub-id pub-id-type="pmcid">PMC5826126</pub-id></element-citation></ref><ref id="B205-antibiotics-13-00801"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinnollareddy</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peake</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>A Roberts</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration</article-title><source>J. Antimicrob. Chemother.</source><year>2018</year><volume>73</volume><fpage>1647</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1093/jac/dky057</pub-id><pub-id pub-id-type="pmid">29506150</pub-id></element-citation></ref><ref id="B206-antibiotics-13-00801"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Pharmacokinetics of multiple doses of teicoplanin in Chinese elderly critical patients</article-title><source>Expert Rev. Clin. Pharmacol.</source><year>2018</year><volume>11</volume><fpage>537</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1080/17512433.2018.1449107</pub-id><pub-id pub-id-type="pmid">29506414</pub-id></element-citation></ref><ref id="B207-antibiotics-13-00801"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassel</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Van Matre</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Wempe</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>MacLaren</surname><given-names>R.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Kiser</surname><given-names>T.H.</given-names></name></person-group><article-title>A Randomized Pharmacokinetic and Pharmacodynamic Evaluation of Every 8-Hour and 12-Hour Dosing Strategies of Vancomycin and Cefepime in Neurocritically ill Patients</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2018</year><volume>38</volume><fpage>921</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1002/phar.2156</pub-id><pub-id pub-id-type="pmid">29906310</pub-id></element-citation></ref><ref id="B208-antibiotics-13-00801"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olbrisch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kisch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thern</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kramme</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rupp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Mail&#228;nder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Raasch</surname><given-names>W.</given-names></name></person-group><article-title>After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients</article-title><source>Naunyn-Schmiedeberg's Arch. Pharmacol.</source><year>2018</year><volume>392</volume><fpage>229</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1007/s00210-018-1573-6</pub-id><pub-id pub-id-type="pmid">30368548</pub-id></element-citation></ref><ref id="B209-antibiotics-13-00801"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrasa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Soraluce</surname><given-names>A.</given-names></name><name name-style="western"><surname>Isla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maynar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Canut</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#225;nchez-Izquierdo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment</article-title><source>J. Crit. Care</source><year>2019</year><volume>50</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2018.11.016</pub-id><pub-id pub-id-type="pmid">30496913</pub-id></element-citation></ref><ref id="B210-antibiotics-13-00801"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>A.-K.</given-names></name><name name-style="western"><surname>David</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bode-B&#246;ger</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Martens-Lobenhoffer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knitsch</surname><given-names>W.</given-names></name><name name-style="western"><surname>Scherneck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kielstein</surname><given-names>J.T.</given-names></name></person-group><article-title>Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>997</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1093/jac/dky511</pub-id><pub-id pub-id-type="pmid">30624668</pub-id></element-citation></ref><ref id="B211-antibiotics-13-00801"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singhan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vadcharavivad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Areepium</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wittayalertpanya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chaijamorn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Srisawat</surname><given-names>N.</given-names></name></person-group><article-title>The effect of direct hemoperfusion with polymyxin B immobilized cartridge on meropenem in critically ill patients requiring renal support</article-title><source>J. Crit. Care</source><year>2019</year><volume>51</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2019.02.007</pub-id><pub-id pub-id-type="pmid">30769293</pub-id></element-citation></ref><ref id="B212-antibiotics-13-00801"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bougl&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dujardin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lep&#232;re</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hamou</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lebreton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>El-Helali</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petijean</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amour</surname><given-names>J.</given-names></name></person-group><article-title>PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support</article-title><source>Anaesth. Crit. Care Pain Med.</source><year>2019</year><volume>38</volume><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1016/j.accpm.2019.02.015</pub-id><pub-id pub-id-type="pmid">30831307</pub-id></element-citation></ref><ref id="B213-antibiotics-13-00801"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhaese</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Thooft</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Verstraete</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Stove</surname><given-names>V.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.J.</given-names></name></person-group><article-title>Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study</article-title><source>J. Crit. Care</source><year>2019</year><volume>52</volume><fpage>75</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2019.04.013</pub-id><pub-id pub-id-type="pmid">30986758</pub-id></element-citation></ref><ref id="B214-antibiotics-13-00801"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guerci</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pape</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thilly</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Germain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Butin-Druoton</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Losser</surname><given-names>M.-R.</given-names></name><name name-style="western"><surname>Birckener</surname><given-names>J.</given-names></name><name name-style="western"><surname>Scala-Bertola</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Serum and peritoneal exudate concentrations after high doses of &#946;-lactams in critically ill patients with severe intra-abdominal infections: An observational prospective study</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>75</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz407</pub-id><pub-id pub-id-type="pmid">31599951</pub-id></element-citation></ref><ref id="B215-antibiotics-13-00801"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>A Roberts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Joynt</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kanji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mudaliar</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Peake</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>D.</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>F.S.</given-names></name><etal/></person-group><article-title>The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>72</volume><fpage>1369</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa224</pub-id><pub-id pub-id-type="pmid">32150603</pub-id></element-citation></ref><ref id="B216-antibiotics-13-00801"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gieling</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Wallenburg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Schouten</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Oever</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Kolwijck</surname><given-names>E.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Pickkers</surname><given-names>P.</given-names></name><name name-style="western"><surname>ter Heine</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility</article-title><source>Clin. Pharmacol. Ther.</source><year>2020</year><volume>108</volume><fpage>770</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1002/cpt.1855</pub-id><pub-id pub-id-type="pmid">32298468</pub-id><pub-id pub-id-type="pmcid">PMC7540326</pub-id></element-citation></ref><ref id="B217-antibiotics-13-00801"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sudhir</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Dipu</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Prabhu</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Edathadathil</surname><given-names>F.</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Prasanna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>V.P.</given-names></name><etal/></person-group><article-title>Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>100</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.08.010</pub-id><pub-id pub-id-type="pmid">32781161</pub-id></element-citation></ref><ref id="B218-antibiotics-13-00801"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>V.-C.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F.-L.L.</given-names></name></person-group><article-title>Pharmacokinetics and dosing of vancomycin in patients undergoing sustained low efficiency daily diafiltration (SLEDD-f): A prospective study</article-title><source>J. Formos. Med Assoc.</source><year>2021</year><volume>120</volume><fpage>737</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2020.08.011</pub-id><pub-id pub-id-type="pmid">32855036</pub-id></element-citation></ref><ref id="B219-antibiotics-13-00801"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Freitas</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Zamoner</surname><given-names>W.</given-names></name><name name-style="western"><surname>dos Reis</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Balbi</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Ponce</surname><given-names>D.</given-names></name></person-group><article-title>Vancomycin for Dialytic Therapy in Critically Ill Patients: Analysis of Its Reduction and the Factors Associated with Subtherapeutic Concentrations</article-title><source>Int. J. Environ. Res. Public Heal.</source><year>2020</year><volume>17</volume><elocation-id>6861</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17186861</pub-id><pub-id pub-id-type="pmcid">PMC7558948</pub-id><pub-id pub-id-type="pmid">32961829</pub-id></element-citation></ref><ref id="B220-antibiotics-13-00801"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#252;hn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Metz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seiler</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wehrfritz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alqudrah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bracht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wagenpfeil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: A prospective, observational single-center study</article-title><source>Crit. Care</source><year>2020</year><volume>24</volume><fpage>664</fpage><pub-id pub-id-type="doi">10.1186/s13054-020-03397-1</pub-id><pub-id pub-id-type="pmid">33239110</pub-id><pub-id pub-id-type="pmcid">PMC7689974</pub-id></element-citation></ref><ref id="B221-antibiotics-13-00801"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corcione</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Nicol&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lupia</surname><given-names>T.</given-names></name><name name-style="western"><surname>Segala</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Pensa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loia</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Di Perri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#8217;avolio</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study</article-title><source>Therapies</source><year>2020</year><volume>76</volume><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.therap.2020.10.003</pub-id><pub-id pub-id-type="pmid">33257012</pub-id></element-citation></ref><ref id="B222-antibiotics-13-00801"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giske</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Eliasson</surname><given-names>E.</given-names></name></person-group><article-title>Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy</article-title><source>Antimicrob. Agents Chemother.</source><year>2021</year><volume>65</volume><pub-id pub-id-type="doi">10.1128/AAC.02029-20</pub-id><pub-id pub-id-type="pmcid">PMC8097483</pub-id><pub-id pub-id-type="pmid">33495227</pub-id></element-citation></ref><ref id="B223-antibiotics-13-00801"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolau</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuti</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Caro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gadzicki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Rizk</surname><given-names>M.L.</given-names></name></person-group><article-title>Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance</article-title><source>Int. J. Antimicrob. Agents</source><year>2021</year><volume>57</volume><fpage>106299</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2021.106299</pub-id><pub-id pub-id-type="pmid">33567333</pub-id></element-citation></ref><ref id="B224-antibiotics-13-00801"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fill&#226;tre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lemaitre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nesseler</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Besset</surname><given-names>S.</given-names></name><name name-style="western"><surname>Launey</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Maamar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Daufresne</surname><given-names>P.</given-names></name><name name-style="western"><surname>Flecher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Le Tulzo</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Impact of extracorporeal membrane oxygenation (ECMO) support on piperacillin exposure in septic patients: A case&#8211;control study</article-title><source>J. Antimicrob. Chemother.</source><year>2021</year><volume>76</volume><fpage>1242</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab031</pub-id><pub-id pub-id-type="pmid">33569597</pub-id></element-citation></ref><ref id="B225-antibiotics-13-00801"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moser</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guertler</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hinic</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dr&#228;ger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rentsch</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sendi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Osthoff</surname><given-names>M.</given-names></name></person-group><article-title>Probability of pharmacological target attainment with flucloxacillin in <italic toggle="yes">Staphylococcus aureus</italic> bloodstream infection: A prospective cohort study of unbound plasma and individual MICs</article-title><source>J. Antimicrob. Chemother.</source><year>2021</year><volume>76</volume><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab089</pub-id><pub-id pub-id-type="pmid">33860325</pub-id><pub-id pub-id-type="pmcid">PMC8212765</pub-id></element-citation></ref><ref id="B226-antibiotics-13-00801"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esteve-Pitarch</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gumucio-Sanguino</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Cobo-Sacrist&#225;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maisterra-Santos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sabater-Riera</surname><given-names>J.</given-names></name><name name-style="western"><surname>P&#233;rez-Fernandez</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Rigo-Bonnin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tubau-Quintano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carratal&#224;</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>2021</year><volume>46</volume><fpage>527</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1007/s13318-021-00694-0</pub-id><pub-id pub-id-type="pmid">34131869</pub-id></element-citation></ref><ref id="B227-antibiotics-13-00801"><label>227.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Pa&#345;&#237;zkov&#225;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mart&#237;nkov&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Havel</surname><given-names>E.</given-names></name><name name-style="western"><surname>&#352;afr&#225;nek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ka&#353;ka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Astapenko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bezou&#353;ka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chl&#225;dek</surname><given-names>J.</given-names></name><name name-style="western"><surname>&#268;ern&#253;</surname><given-names>V.</given-names></name></person-group><article-title>Additional File 1 of Impact of Cumulative Fluid Balance on the Pharmacokinetics of Extended Infusion Meropenem in Critically Ill Patients with Sepsis</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34274013/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/34274013/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-18">(accessed on 18 July 2024)</date-in-citation><pub-id pub-id-type="doi">10.6084/m9.figshare.15000155</pub-id><pub-id pub-id-type="pmcid">PMC8285835</pub-id><pub-id pub-id-type="pmid">34274013</pub-id></element-citation></ref><ref id="B228-antibiotics-13-00801"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liebchen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Paal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bucher</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irlbeck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name></person-group><article-title>Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study</article-title><source>J. Crit. Care</source><year>2021</year><volume>67</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2021.09.011</pub-id><pub-id pub-id-type="pmid">34628123</pub-id></element-citation></ref><ref id="B229-antibiotics-13-00801"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messiano</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Junior</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Junior</surname><given-names>E.M.d.S.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>D.D.S.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>S.R.C.J.</given-names></name></person-group><article-title>Therapeutic Target Attainment of 3-Hour Extended Infusion of Meropenem in Patients With Septic Burns</article-title><source>Clin. Ther.</source><year>2022</year><pub-id pub-id-type="doi">10.1016/j.clinthera.2022.02.007</pub-id><pub-id pub-id-type="pmid">35260257</pub-id></element-citation></ref><ref id="B230-antibiotics-13-00801"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greimel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kallee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irlbeck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>I.</given-names></name><name name-style="western"><surname>Liebchen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name></person-group><article-title>Serum linezolid concentrations are reduced in critically ill patients with pulmonary infections: A prospective observational study</article-title><source>J. Crit. Care</source><year>2022</year><volume>71</volume><fpage>154100</fpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2022.154100</pub-id><pub-id pub-id-type="pmid">35780622</pub-id></element-citation></ref><ref id="B231-antibiotics-13-00801"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shekar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V.</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>F.</given-names></name><name name-style="western"><surname>Buscher</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Corley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gilder</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2023</year><volume>207</volume><fpage>704</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1164/rccm.202207-1393OC</pub-id><pub-id pub-id-type="pmid">36215036</pub-id></element-citation></ref><ref id="B232-antibiotics-13-00801"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smeets</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>de Geus</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Rietveld</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rietdijk</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>N.G.</given-names></name></person-group><article-title>Pursuing the Real Vancomycin Clearance during Continuous Renal Replacement Therapy in Intensive Care Unit Patients: Is There Adequate Target Attainment?</article-title><source>Blood Purif.</source><year>2023</year><volume>52</volume><fpage>652</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1159/000530815</pub-id><pub-id pub-id-type="pmid">37311418</pub-id></element-citation></ref><ref id="B233-antibiotics-13-00801"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Launay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balluet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gergele</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>V.</given-names></name><name name-style="western"><surname>Morel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beuret</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mariat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thiery</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ragey</surname><given-names>S.P.</given-names></name></person-group><article-title>Towards optimization of ceftazidime dosing in obese ICU patients: The end of the &#8216;one-size-fits-all&#8217; approach?</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>78</volume><fpage>2968</fpage><lpage>2975</lpage><pub-id pub-id-type="doi">10.1093/jac/dkad339</pub-id><pub-id pub-id-type="pmid">37919244</pub-id></element-citation></ref><ref id="B234-antibiotics-13-00801"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bruguerolle</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Freney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fleurette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meugnier</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gouin</surname><given-names>F.</given-names></name></person-group><article-title>Ofloxacin pharmacokinetics in mechanically ventilated patients</article-title><source>Antimicrob. Agents Chemother.</source><year>1991</year><volume>35</volume><fpage>1582</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1128/AAC.35.8.1582</pub-id><pub-id pub-id-type="pmid">1929329</pub-id><pub-id pub-id-type="pmcid">PMC245222</pub-id></element-citation></ref><ref id="B235-antibiotics-13-00801"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akers</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Niece</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Cota</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>C.K.</given-names></name></person-group><article-title>Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients</article-title><source>J. Trauma: Inj. Infect. Crit. Care</source><year>2014</year><volume>77</volume><fpage>S163</fpage><lpage>S170</lpage><pub-id pub-id-type="doi">10.1097/TA.0000000000000191</pub-id><pub-id pub-id-type="pmid">24770557</pub-id></element-citation></ref><ref id="B236-antibiotics-13-00801"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Sanches-Giraud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>A.M.R.R.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gemperli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>S.R.</given-names></name></person-group><article-title>Imipenem in burn patients: Pharmacokinetic profile and PK/PD target attainment</article-title><source>J. Antibiot.</source><year>2014</year><volume>68</volume><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1038/ja.2014.121</pub-id><pub-id pub-id-type="pmid">25227503</pub-id></element-citation></ref><ref id="B237-antibiotics-13-00801"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Barmparas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mehrzadi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>E.J.</given-names></name></person-group><article-title>Reducing acute kidney injury due to vancomycin in trauma patients</article-title><source>J. Trauma: Inj. Infect. Crit. Care</source><year>2016</year><volume>81</volume><fpage>352</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1097/TA.0000000000001105</pub-id><pub-id pub-id-type="pmid">27192471</pub-id></element-citation></ref><ref id="B238-antibiotics-13-00801"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mokline</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gharsallah</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rahmani</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gaies</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tabelsi</surname><given-names>S.</given-names></name><name name-style="western"><surname>A Messadi</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of Linezolid in burn patients</article-title><source>Ann. Burn. Fire Disasters </source><year>2018</year><volume>31</volume><fpage>118</fpage><lpage>121</lpage><pub-id pub-id-type="pmcid">PMC6199010</pub-id><pub-id pub-id-type="pmid">30374263</pub-id></element-citation></ref><ref id="B239-antibiotics-13-00801"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>I.</given-names></name></person-group><article-title>High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration</article-title><source>Hemodial. Int.</source><year>2019</year><volume>23</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1111/hdi.12704</pub-id><pub-id pub-id-type="pmid">30714672</pub-id></element-citation></ref><ref id="B240-antibiotics-13-00801"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovacevic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miljkovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mikov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Satara</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Dragic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Momcicevic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kovacevic</surname><given-names>P.</given-names></name></person-group><article-title>The Effect of Hypoalbuminemia on the Therapeutic Concentration and Dosage of Vancomycin in Critically Ill Septic Patients in Low-Resource Countries</article-title><source>Dose-Response</source><year>2019</year><volume>17</volume><pub-id pub-id-type="doi">10.1177/1559325819850419</pub-id><pub-id pub-id-type="pmcid">PMC6537498</pub-id><pub-id pub-id-type="pmid">31205457</pub-id></element-citation></ref><ref id="B241-antibiotics-13-00801"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.-Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>S.-C.</given-names></name></person-group><article-title>Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/pharmacodynamic target in Asian ICU population: A prospective observational study</article-title><source>Infect. Drug Resist.</source><year>2019</year><volume>ume 12</volume><fpage>2531</fpage><lpage>2541</lpage><pub-id pub-id-type="doi">10.2147/IDR.S213183</pub-id><pub-id pub-id-type="pmcid">PMC6701640</pub-id><pub-id pub-id-type="pmid">31496765</pub-id></element-citation></ref><ref id="B242-antibiotics-13-00801"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morbitzer</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Rhoney</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Dehne</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>J.D.</given-names></name></person-group><article-title>Enhanced renal clearance and impact on vancomycin pharmacokinetic parameters in patients with hemorrhagic stroke</article-title><source>J. Intensive Care</source><year>2019</year><volume>7</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s40560-019-0408-y</pub-id><pub-id pub-id-type="pmid">31832200</pub-id><pub-id pub-id-type="pmcid">PMC6868795</pub-id></element-citation></ref><ref id="B243-antibiotics-13-00801"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breilh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Honore</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>De Bels</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gordien</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Fleureau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dewitte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coquin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roz&#233;</surname><given-names>H.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: Lessons learned from an ancillary study of the IVOIRE trial</article-title><source>J. Transl. Intern. Med.</source><year>2019</year><volume>7</volume><fpage>155</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.2478/jtim-2019-0031</pub-id><pub-id pub-id-type="pmcid">PMC6985915</pub-id><pub-id pub-id-type="pmid">32010602</pub-id></element-citation></ref><ref id="B244-antibiotics-13-00801"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>L.</given-names></name><name name-style="western"><surname>Neto</surname><given-names>L.V.P.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>S.R.C.J.</given-names></name><name name-style="western"><surname>Sanches</surname><given-names>C.</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>A.S.</given-names></name></person-group><article-title>Pharmacokinetic and Pharmacodynamic Characteristics of Vancomycin and Meropenem in Critically Ill Patients Receiving Sustained Low-efficiency Dialysis</article-title><source>Clin. Ther.</source><year>2020</year><volume>42</volume><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2020.02.011</pub-id><pub-id pub-id-type="pmid">32199609</pub-id></element-citation></ref><ref id="B245-antibiotics-13-00801"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoud</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Avedissian</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Al-Qamari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bohling</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>M.H.</given-names></name></person-group><article-title>Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study</article-title><source>Clin. Pharmacokinet.</source><year>2020</year><volume>59</volume><fpage>1575</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00902-1</pub-id><pub-id pub-id-type="pmid">32468446</pub-id><pub-id pub-id-type="pmcid">PMC7704765</pub-id></element-citation></ref><ref id="B246-antibiotics-13-00801"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veillette</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Winans</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Maskiewicz</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Forland</surname><given-names>S.C.</given-names></name></person-group><article-title>Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin&#8211;Tazobactam in Obese Patients</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>2021</year><volume>46</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1007/s13318-021-00677-1</pub-id><pub-id pub-id-type="pmid">33743171</pub-id><pub-id pub-id-type="pmcid">PMC8093170</pub-id></element-citation></ref><ref id="B247-antibiotics-13-00801"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gijsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dreesen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Daele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Annaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Debaveye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wauters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spriet</surname><given-names>I.</given-names></name></person-group><article-title>Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>557</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10050557</pub-id><pub-id pub-id-type="pmid">34064676</pub-id><pub-id pub-id-type="pmcid">PMC8151456</pub-id></element-citation></ref><ref id="B248-antibiotics-13-00801"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Dose Optimization of Teicoplanin for Critically Ill Patients With Renal Dysfunction and Continuous Renal Replacement Therapy: Experience From a Prospective Interventional Study</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><elocation-id>817401</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.817401</pub-id><pub-id pub-id-type="pmid">35350761</pub-id><pub-id pub-id-type="pmcid">PMC8957950</pub-id></element-citation></ref><ref id="B249-antibiotics-13-00801"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Association between Augmented Renal Clearance and Inadequate Vancomycin Pharmacokinetic/Pharmacodynamic Targets in Chinese Adult Patients: A Prospective Observational Study</article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><elocation-id>837</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11070837</pub-id><pub-id pub-id-type="pmid">35884091</pub-id><pub-id pub-id-type="pmcid">PMC9312211</pub-id></element-citation></ref><ref id="B250-antibiotics-13-00801"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Munzel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Roehr</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>O.</given-names></name><name name-style="western"><surname>Higuita</surname><given-names>L.M.S.</given-names></name><name name-style="western"><surname>Wied</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rosenberger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haeberle</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Ngamsri</surname><given-names>K.-C.</given-names></name></person-group><article-title>Daptomycin Pharmacokinetics in Blood and Wound Fluid in Critical Ill Patients with Left Ventricle Assist Devices</article-title><source>Antibiotics</source><year>2023</year><volume>12</volume><elocation-id>904</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12050904</pub-id><pub-id pub-id-type="pmid">37237807</pub-id><pub-id pub-id-type="pmcid">PMC10215934</pub-id></element-citation></ref><ref id="B251-antibiotics-13-00801"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tikiso</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fuhrmann</surname><given-names>V.</given-names></name><name name-style="western"><surname>K&#246;nig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jarczak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iwersen-Bergmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kluge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Grensemann</surname><given-names>J.</given-names></name></person-group><article-title>Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: An observational study</article-title><source>Ann. Intensive Care</source><year>2023</year><volume>13</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s13613-023-01184-z</pub-id><pub-id pub-id-type="pmid">37698659</pub-id><pub-id pub-id-type="pmcid">PMC10497461</pub-id></element-citation></ref><ref id="B252-antibiotics-13-00801"><label>252.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>A Roberts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R.</given-names></name></person-group><article-title>Additional File 1 of A multicenter Study on the Effect of Continuous Hemodiafiltration Intensity on Antibiotic Pharmacokinetics</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25881576/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/25881576/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-18">(accessed on 18 July 2024)</date-in-citation><pub-id pub-id-type="doi">10.6084/m9.figshare.15094927</pub-id><pub-id pub-id-type="pmcid">PMC4404619</pub-id><pub-id pub-id-type="pmid">25881576</pub-id></element-citation></ref><ref id="B253-antibiotics-13-00801"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Weinelt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>I.</given-names></name><name name-style="western"><surname>Paal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irlbeck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C.</given-names></name><name name-style="western"><surname>Briegel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liebchen</surname><given-names>U.</given-names></name></person-group><article-title>Does the cytokine adsorber CytoSorb<sup>&#174;</sup> reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study</article-title><source>Ann. Intensive Care</source><year>2022</year><volume>12</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s13613-022-01017-5</pub-id><pub-id pub-id-type="pmid">35599248</pub-id><pub-id pub-id-type="pmcid">PMC9124739</pub-id></element-citation></ref><ref id="B254-antibiotics-13-00801"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wulkersdorfer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Amann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fochtmann-Frana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al Jalali</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kurdina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lackner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Effect of albumin substitution on pharmacokinetics of piperacillin/tazobactam in patients with severe burn injury admitted to the ICU</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>79</volume><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1093/jac/dkad368</pub-id><pub-id pub-id-type="pmcid">PMC10832600</pub-id><pub-id pub-id-type="pmid">38069908</pub-id></element-citation></ref><ref id="B255-antibiotics-13-00801"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahrami</surname><given-names>B.</given-names></name><name name-style="western"><surname>Najmeddin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rouini</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khezrnia</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Sharifnia</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Mojtahedzadeh</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of Amikacin Pharmacokinetics in Critically Ill Patients with Intra-abdominal Sepsis</article-title><source>Adv. Pharm. Bull.</source><year>2019</year><volume>10</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.15171/apb.2020.014</pub-id><pub-id pub-id-type="pmid">32002369</pub-id><pub-id pub-id-type="pmcid">PMC6983982</pub-id></element-citation></ref><ref id="B256-antibiotics-13-00801"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Busse</surname><given-names>D.</given-names></name><name name-style="western"><surname>Petroff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ehmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hochst&#228;dt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Girrbach</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kees</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>1067</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9041067</pub-id><pub-id pub-id-type="pmid">32283731</pub-id><pub-id pub-id-type="pmcid">PMC7230366</pub-id></element-citation></ref><ref id="B257-antibiotics-13-00801"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Bono</surname><given-names>V.</given-names></name><name name-style="western"><surname>Giacobbe</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Marchese</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parisini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fucile</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coppo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Arena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Molin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martelli</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?</article-title><source>Virulence</source><year>2016</year><volume>8</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1080/21505594.2016.1213476</pub-id><pub-id pub-id-type="pmid">27430122</pub-id><pub-id pub-id-type="pmcid">PMC5963200</pub-id></element-citation></ref><ref id="B258-antibiotics-13-00801"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Pharmacokinetic/Pharmacodynamic Parameters of Linezolid in the Epithelial Lining Fluid of Patients With Sepsis</article-title><source>J. Clin. Pharmacol.</source><year>2022</year><volume>62</volume><fpage>891</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1002/jcph.2031</pub-id><pub-id pub-id-type="pmid">35049077</pub-id></element-citation></ref><ref id="B259-antibiotics-13-00801"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rudiger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chiesa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jetter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rentsch</surname><given-names>K.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>D.</given-names></name><name name-style="western"><surname>B&#233;chir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maggiorini</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacokinetics of Daily Daptomycin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy</article-title><source>Chemotherapy</source><year>2013</year><volume>59</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1159/000353400</pub-id><pub-id pub-id-type="pmid">24051895</pub-id></element-citation></ref><ref id="B260-antibiotics-13-00801"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corcione</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#8217;avolio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loia</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Pensa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Segala</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>De Nicol&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fatiguso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Perri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2020</year><volume>20</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2019.06.011</pub-id><pub-id pub-id-type="pmid">31207380</pub-id></element-citation></ref><ref id="B261-antibiotics-13-00801"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>Selection of piperacillin/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: A randomized controlled study</article-title><source>Ther. Clin. Risk Manag.</source><year>2018</year><volume>14</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.2147/TCRM.S145681</pub-id><pub-id pub-id-type="pmid">29317824</pub-id><pub-id pub-id-type="pmcid">PMC5743125</pub-id></element-citation></ref><ref id="B262-antibiotics-13-00801"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Starre</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Kolz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lemmens</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Faix</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>C.</given-names></name></person-group><article-title>Vancomycin plasma concentrations in cardiac surgery with the use of profound hypothermic circulatory arrest</article-title><source>Eur. J. Cardio-Thoracic Surg.</source><year>2010</year><volume>38</volume><fpage>741</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.ejcts.2010.03.029</pub-id><pub-id pub-id-type="pmid">20663677</pub-id></element-citation></ref><ref id="B263-antibiotics-13-00801"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triginer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J.</given-names></name><name name-style="western"><surname>Torrent</surname><given-names>J.</given-names></name><name name-style="western"><surname>Benito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Net</surname><given-names>A.</given-names></name></person-group><article-title>Gentamicin volume of distribution in critically ill septic patients</article-title><source>Intensive Care Med.</source><year>1990</year><volume>16</volume><fpage>303</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1007/BF01706354</pub-id><pub-id pub-id-type="pmid">2212254</pub-id></element-citation></ref><ref id="B264-antibiotics-13-00801"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.Y.</given-names></name></person-group><article-title>Factors affecting gentamicin pharmacokinetics in septic patients</article-title><source>Acta Anaesthesiol. Scand.</source><year>1999</year><volume>43</volume><fpage>726</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1034/j.1399-6576.1999.430707.x</pub-id><pub-id pub-id-type="pmid">10456812</pub-id></element-citation></ref><ref id="B265-antibiotics-13-00801"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rebuck</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>E.</given-names></name></person-group><article-title>Pharmacokinetics of Intravenous and Oral Levofloxacin in Critically Ill Adults in a Medical Intensive Care Unit</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2002</year><volume>22</volume><fpage>1216</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1592/phco.22.15.1216.33484</pub-id><pub-id pub-id-type="pmid">12389872</pub-id></element-citation></ref><ref id="B266-antibiotics-13-00801"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belzberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cornwell</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sava</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Velmahos</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>M.A.</given-names></name></person-group><article-title>Imipenem Levels Are Not Predictable in the Critically Ill Patient</article-title><source>J. Trauma: Inj. Infect. Crit. Care</source><year>2004</year><volume>56</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1097/01.TA.0000056164.26493.28</pub-id><pub-id pub-id-type="pmid">14749576</pub-id></element-citation></ref><ref id="B267-antibiotics-13-00801"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarro</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gandarillas</surname><given-names>C.-I.C.</given-names></name><name name-style="western"><surname>Lerma</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Menacho</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Dom&#237;nguez-Gil</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics and Pharmacodynamics of Levofloxacin in Intensive Care Patients</article-title><source>Clin. Pharmacokinet.</source><year>2005</year><volume>44</volume><fpage>627</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.2165/00003088-200544060-00004</pub-id><pub-id pub-id-type="pmid">15910010</pub-id></element-citation></ref><ref id="B268-antibiotics-13-00801"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Zanten</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Polderman</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>van Geijlswijk</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Schouten</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Girbes</surname><given-names>A.R.</given-names></name></person-group><article-title>Ciprofloxacin pharmacokinetics in critically ill patients: A prospective cohort study</article-title><source>J. Crit. Care</source><year>2008</year><volume>23</volume><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2007.11.011</pub-id><pub-id pub-id-type="pmid">18725050</pub-id></element-citation></ref><ref id="B269-antibiotics-13-00801"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brink</surname><given-names>A.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schillack</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kiem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis</article-title><source>Int. J. Antimicrob. Agents</source><year>2008</year><volume>33</volume><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2008.10.005</pub-id><pub-id pub-id-type="pmid">19091521</pub-id></element-citation></ref><ref id="B270-antibiotics-13-00801"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapuis</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Giannoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>A Majcherczyk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chiol&#233;ro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schaller</surname><given-names>M.-D.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Bolay</surname><given-names>S.</given-names></name><name name-style="western"><surname>A D&#233;costerd</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bugnon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moreillon</surname><given-names>P.</given-names></name></person-group><article-title>Prospective monitoring of cefepime in intensive care unit adult patients</article-title><source>Crit. Care</source><year>2010</year><volume>14</volume><fpage>R51</fpage><pub-id pub-id-type="doi">10.1186/cc8941</pub-id><pub-id pub-id-type="pmid">20359352</pub-id><pub-id pub-id-type="pmcid">PMC2887166</pub-id></element-citation></ref><ref id="B271-antibiotics-13-00801"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aubron</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corallo</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Nunn</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Dooley</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A.C.</given-names></name></person-group><article-title>Evaluation of the Accuracy of a Pharmacokinetic Dosing Program in Predicting Serum Vancomycin Concentrations in Critically Ill Patients</article-title><source>Ann. Pharmacother.</source><year>2011</year><volume>45</volume><fpage>1193</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1345/aph.1Q195</pub-id><pub-id pub-id-type="pmid">21896920</pub-id></element-citation></ref><ref id="B272-antibiotics-13-00801"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>Y.S.</given-names></name></person-group><article-title>Optimal Dose of Vancomycin for Treating Methicillin-Resistant Staphylococcus Aureus Pneumonia in Critically Ill Patients</article-title><source>Anaesth. Intensive Care</source><year>2011</year><volume>39</volume><fpage>1030</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1177/0310057X1103900608</pub-id><pub-id pub-id-type="pmid">22165354</pub-id></element-citation></ref><ref id="B273-antibiotics-13-00801"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karnik</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Sridharan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kadam</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Naidu</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Namjoshi</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gore</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Surase</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>P.R.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2013</year><volume>69</volume><fpage>1429</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1007/s00228-013-1493-9</pub-id><pub-id pub-id-type="pmid">23508665</pub-id></element-citation></ref><ref id="B274-antibiotics-13-00801"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koegelenberg</surname><given-names>C.F.N.</given-names></name><name name-style="western"><surname>Nortje</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lalla</surname><given-names>U.</given-names></name><name name-style="western"><surname>Enslin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Irusen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Rosenkranz</surname><given-names>B.</given-names></name><name name-style="western"><surname>I Seifart</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bolliger</surname><given-names>C.T.</given-names></name></person-group><article-title>The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care</article-title><source>South Afr. Med. J.</source><year>2013</year><volume>103</volume><fpage>394</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.7196/SAMJ.6344</pub-id><pub-id pub-id-type="pmid">23725959</pub-id></element-citation></ref><ref id="B275-antibiotics-13-00801"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Montmollin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bouadma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gault</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mourvillier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mariotte</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chemam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Massias</surname><given-names>L.</given-names></name><name name-style="western"><surname>Papy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tubach</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen</article-title><source>Intensive Care Med.</source><year>2014</year><volume>40</volume><fpage>998</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1007/s00134-014-3276-x</pub-id><pub-id pub-id-type="pmid">24687298</pub-id></element-citation></ref><ref id="B276-antibiotics-13-00801"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takasu</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nabeta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirayu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yoshiyama</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections</article-title><source>J. Infect. Chemother.</source><year>2015</year><volume>21</volume><fpage>449</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2015.02.002</pub-id><pub-id pub-id-type="pmid">25726436</pub-id></element-citation></ref><ref id="B277-antibiotics-13-00801"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dulhunty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaukonen</surname><given-names>K.-M.</given-names></name><name name-style="western"><surname>Koulenti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>71</volume><fpage>196</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv288</pub-id><pub-id pub-id-type="pmid">26433783</pub-id></element-citation></ref><ref id="B278-antibiotics-13-00801"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zander</surname><given-names>J.</given-names></name><name name-style="western"><surname>D&#246;bbeler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nagel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huseyn-Zada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name></person-group><article-title>Piperacillin concentration in relation to therapeutic range in critically ill patients&#8212;A prospective observational study</article-title><source>Crit. Care</source><year>2016</year><volume>20</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/s13054-016-1255-z</pub-id><pub-id pub-id-type="pmid">27039986</pub-id><pub-id pub-id-type="pmcid">PMC4819271</pub-id></element-citation></ref><ref id="B279-antibiotics-13-00801"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allou</surname><given-names>N.</given-names></name><name name-style="western"><surname>Charifou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Augustin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Galas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Valance</surname><given-names>D.</given-names></name><name name-style="western"><surname>Corradi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martinet</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vandroux</surname><given-names>D.</given-names></name><name name-style="western"><surname>Allyn</surname><given-names>J.</given-names></name></person-group><article-title>A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2016</year><volume>35</volume><fpage>1187</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1007/s10096-016-2652-6</pub-id><pub-id pub-id-type="pmid">27142585</pub-id></element-citation></ref><ref id="B280-antibiotics-13-00801"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obara</surname><given-names>V.Y.</given-names></name><name name-style="western"><surname>Zacas</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Carrilho</surname><given-names>C.M.D.d.M.</given-names></name><name name-style="western"><surname>Delfino</surname><given-names>V.D.A.</given-names></name></person-group><article-title>Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients</article-title><source>Rev. Bras. Ter. Intensive</source><year>2016</year><volume>28</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.5935/0103-507X.20160071</pub-id><pub-id pub-id-type="pmcid">PMC5225912</pub-id><pub-id pub-id-type="pmid">28099635</pub-id></element-citation></ref><ref id="B281-antibiotics-13-00801"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakke</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sporsem</surname><given-names>H.</given-names></name><name name-style="western"><surname>Von der Lippe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nord&#248;y</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nyrer&#248;d</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Sandvik</surname><given-names>L.</given-names></name><name name-style="western"><surname>H&#229;rvig</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Bugge</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Helset</surname><given-names>E.</given-names></name></person-group><article-title>Vancomycin levels are frequently subtherapeutic in critically ill patients: A prospective observational study</article-title><source>Acta Anaesthesiol. Scand.</source><year>2017</year><volume>61</volume><fpage>627</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1111/aas.12897</pub-id><pub-id pub-id-type="pmid">28444760</pub-id><pub-id pub-id-type="pmcid">PMC5485054</pub-id></element-citation></ref><ref id="B282-antibiotics-13-00801"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Company</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Concha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aroca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frasquet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Remedios-Marqu&#233;s</surname><given-names>M.</given-names></name><collab>Castellanos-Ortega</collab></person-group><article-title>Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2018</year><volume>12</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2017.09.019</pub-id><pub-id pub-id-type="pmid">29017888</pub-id></element-citation></ref><ref id="B283-antibiotics-13-00801"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calpini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lamoth</surname><given-names>F.</given-names></name><name name-style="western"><surname>Decosterd</surname><given-names>L.</given-names></name><name name-style="western"><surname>Robatel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>O.</given-names></name></person-group><article-title>Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections</article-title><source>J. Antimicrob. Chemother.</source><year>2018</year><volume>73</volume><fpage>3413</fpage><lpage>3422</lpage><pub-id pub-id-type="doi">10.1093/jac/dky370</pub-id><pub-id pub-id-type="pmid">30304491</pub-id></element-citation></ref><ref id="B284-antibiotics-13-00801"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Association Between Pathophysiology and Volume of Distribution Among Patients With Sepsis or Septic Shock Treated With Imipenem: A Prospective Cohort Study</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>221</volume><fpage>S272</fpage><lpage>S278</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz651</pub-id><pub-id pub-id-type="pmid">32176787</pub-id></element-citation></ref><ref id="B285-antibiotics-13-00801"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helset</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nord&#248;y</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sporsem</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bakke</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Bugge</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Gammelsrud</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Zucknick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lippe</surname><given-names>E.</given-names></name><name name-style="western"><surname>von der Lippe</surname><given-names>E.</given-names></name></person-group><article-title>Factors increasing the risk of inappropriate vancomycin therapy in ICU patients: A prospective observational study</article-title><source>Acta Anaesthesiol. Scand.</source><year>2020</year><volume>64</volume><fpage>1295</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1111/aas.13658</pub-id><pub-id pub-id-type="pmid">32578201</pub-id></element-citation></ref><ref id="B286-antibiotics-13-00801"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ram</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhati</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Suri</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Meshram</surname><given-names>G.G.</given-names></name></person-group><article-title>Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2021</year><volume>128</volume><fpage>128</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1111/bcpt.13482</pub-id><pub-id pub-id-type="pmid">33245629</pub-id></element-citation></ref><ref id="B287-antibiotics-13-00801"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>An evaluation on the association of vancomycin trough concentration with mortality in critically ill patients: A multicenter retrospective study</article-title><source>Clin. Transl. Sci.</source><year>2021</year><volume>14</volume><fpage>1780</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1111/cts.13020</pub-id><pub-id pub-id-type="pmid">33835715</pub-id><pub-id pub-id-type="pmcid">PMC8504840</pub-id></element-citation></ref><ref id="B288-antibiotics-13-00801"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niibe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>T.-A.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>I.</given-names></name></person-group><article-title>Identification of factors affecting meropenem pharmacokinetics in critically ill patients: Impact of inflammation on clearance</article-title><source>J. Infect. Chemother.</source><year>2022</year><volume>28</volume><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2021.12.017</pub-id><pub-id pub-id-type="pmid">34973877</pub-id></element-citation></ref><ref id="B289-antibiotics-13-00801"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paruk</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gous</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chausse</surname><given-names>J.</given-names></name><name name-style="western"><surname>Milne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Said</surname><given-names>M.</given-names></name></person-group><article-title>Evaluating the usefulness of the estimated glomerular filtration rate for determination of imipenem dosage in critically ill patients</article-title><source>South Afr. Med J.</source><year>2022</year><volume>112</volume><fpage>765</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.7196/SAMJ.2022.v112i9.16371</pub-id><pub-id pub-id-type="pmid">36214037</pub-id></element-citation></ref><ref id="B290-antibiotics-13-00801"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helset</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sporsem</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thorstensen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nord&#248;y</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gammelsrud</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Hanssen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ponzi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>von der Lippe</surname><given-names>E.</given-names></name></person-group><article-title>Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in ICU patients: A prospective observational study</article-title><source>Acta Anaesthesiol. Scand.</source><year>2024</year><volume>68</volume><fpage>502</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1111/aas.14376</pub-id><pub-id pub-id-type="pmid">38286568</pub-id></element-citation></ref><ref id="B291-antibiotics-13-00801"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lejbman</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Torisson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Resman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sj&#246;vall</surname><given-names>F.</given-names></name></person-group><article-title>Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study</article-title><source>Acta Anaesthesiol. Scand.</source><year>2024</year><volume>68</volume><fpage>530</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1111/aas.14382</pub-id><pub-id pub-id-type="pmid">38407447</pub-id></element-citation></ref><ref id="B292-antibiotics-13-00801"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beckhouse</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Whyte</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Byth</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Napier</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.J.</given-names></name></person-group><article-title>Altered Aminoglycoside Pharmacokinetics in the Critically Ill</article-title><source>Anaesth. Intensive Care</source><year>1988</year><volume>16</volume><fpage>418</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1177/0310057X8801600406</pub-id><pub-id pub-id-type="pmid">3232800</pub-id></element-citation></ref><ref id="B293-antibiotics-13-00801"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeitlinger</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leitner</surname><given-names>I.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Joukhadar</surname><given-names>C.</given-names></name></person-group><article-title>Clinical Scoring System for the Prediction of Target Site Penetration of Antimicrobials in Patients with Sepsis</article-title><source>Clin. Pharmacokinet.</source><year>2007</year><volume>46</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.2165/00003088-200746010-00004</pub-id><pub-id pub-id-type="pmid">17201459</pub-id></element-citation></ref><ref id="B294-antibiotics-13-00801"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cristallini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hites</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kabtouri</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Beumier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Creteur</surname><given-names>J.</given-names></name><etal/></person-group><article-title>New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>4750</fpage><lpage>4756</lpage><pub-id pub-id-type="doi">10.1128/AAC.00330-16</pub-id><pub-id pub-id-type="pmid">27216073</pub-id><pub-id pub-id-type="pmcid">PMC4958221</pub-id></element-citation></ref><ref id="B295-antibiotics-13-00801"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Minichmayr</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huisinga</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: A prospective observational study</article-title><source>Crit. Care</source><year>2017</year><volume>21</volume><fpage>263</fpage><pub-id pub-id-type="doi">10.1186/s13054-017-1829-4</pub-id><pub-id pub-id-type="pmid">29058601</pub-id><pub-id pub-id-type="pmcid">PMC5651591</pub-id></element-citation></ref><ref id="B296-antibiotics-13-00801"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coste</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deslandes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jalin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corvec</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caillon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boutoille</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gr&#233;goire</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bretonni&#232;re</surname><given-names>C.</given-names></name></person-group><article-title>PK/PD targets of amikacin and gentamicin in ICU patients</article-title><source>Med. Et Mal. Infect.</source><year>2019</year><volume>50</volume><fpage>709</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.medmal.2019.12.003</pub-id><pub-id pub-id-type="pmid">31883736</pub-id></element-citation></ref><ref id="B297-antibiotics-13-00801"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logre</surname><given-names>E.</given-names></name><name name-style="western"><surname>Enser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dubert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Claudinon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grall</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mentec</surname><given-names>H.</given-names></name><name name-style="western"><surname>Montravers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pajot</surname><given-names>O.</given-names></name></person-group><article-title>Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: A prospective database</article-title><source>Ann. Intensive Care</source><year>2020</year><volume>10</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s13613-020-00685-5</pub-id><pub-id pub-id-type="pmid">32514769</pub-id><pub-id pub-id-type="pmcid">PMC7276966</pub-id></element-citation></ref><ref id="B298-antibiotics-13-00801"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Corte</surname><given-names>T.</given-names></name><name name-style="western"><surname>Verhaeghe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dhaese</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Vooren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boelens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Verstraete</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Stove</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ongenae</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Bus</surname><given-names>L.</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: A prospective single center observational study</article-title><source>Ann. Intensive Care</source><year>2023</year><volume>13</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s13613-023-01129-6</pub-id><pub-id pub-id-type="pmid">37119362</pub-id><pub-id pub-id-type="pmcid">PMC10148758</pub-id></element-citation></ref><ref id="B299-antibiotics-13-00801"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilhaumou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chevrier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Setti</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Jouve</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marsot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Julian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Blin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Simeone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lagier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mokart</surname><given-names>D.</given-names></name><etal/></person-group><article-title>&#946;-Lactam Pharmacokinetic/Pharmacodynamic Target Attainment in Intensive Care Unit Patients: A Prospective, Observational, Cohort Study</article-title><source>Antibiotics</source><year>2023</year><volume>12</volume><elocation-id>1289</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12081289</pub-id><pub-id pub-id-type="pmid">37627709</pub-id><pub-id pub-id-type="pmcid">PMC10451857</pub-id></element-citation></ref><ref id="B300-antibiotics-13-00801"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Haffaf</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marsot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hachemi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pesout</surname><given-names>T.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>V.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D.</given-names></name></person-group><article-title>Exposure levels and target attainment of piperacillin/tazobactam in adult patients admitted to the intensive care unit: A prospective observational study</article-title><source>Can. J. Anaesth.</source><year>2024</year><volume>71</volume><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1007/s12630-023-02689-8</pub-id><pub-id pub-id-type="pmid">38243099</pub-id></element-citation></ref><ref id="B301-antibiotics-13-00801"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campassi</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Masevicius</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Vazquez</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Moseinco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Previgliano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rubatto</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Benites</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Estenssoro</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Augmented renal clearance in critically ill patients: Incidence, associated factors and effects on vancomycin treatment</article-title><source>Rev. Bras. Ter. Intensive</source><year>2014</year><volume>26</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.5935/0103-507X.20140003</pub-id><pub-id pub-id-type="pmcid">PMC4031886</pub-id><pub-id pub-id-type="pmid">24770684</pub-id></element-citation></ref><ref id="B302-antibiotics-13-00801"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Comparative pharmacokinetics of polymyxin B in critically ill elderly patients with extensively drug-resistant gram-negative bacteria infections</article-title><source>Front. Pharmacol.</source><year>2024</year><volume>15</volume><elocation-id>1347130</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2024.1347130</pub-id><pub-id pub-id-type="pmid">38362145</pub-id><pub-id pub-id-type="pmcid">PMC10867212</pub-id></element-citation></ref><ref id="B303-antibiotics-13-00801"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frazee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rule</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Lieske</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Kashani</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Virk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuper</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Dierkhising</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>N.</given-names></name></person-group><article-title>Cystatin C&#8211;Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project</article-title><source>Am. J. Kidney Dis.</source><year>2017</year><volume>69</volume><fpage>658</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.11.016</pub-id><pub-id pub-id-type="pmid">28131530</pub-id></element-citation></ref><ref id="B304-antibiotics-13-00801"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name></person-group><article-title>Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2024</year><volume>36</volume><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2024.01.004</pub-id><pub-id pub-id-type="pmid">38272210</pub-id></element-citation></ref><ref id="B305-antibiotics-13-00801"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.-X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>T.-T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.-S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.-J.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Y.-G.</given-names></name></person-group><article-title>Influence of continuous renal replacement therapy on the plasma concentration of tigecycline in patients with septic shock: A prospective observational study</article-title><source>Front. Pharmacol.</source><year>2023</year><volume>14</volume><elocation-id>1118788</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2023.1118788</pub-id><pub-id pub-id-type="pmid">36969878</pub-id><pub-id pub-id-type="pmcid">PMC10034132</pub-id></element-citation></ref><ref id="B306-antibiotics-13-00801"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poli</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Simoni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Longchamp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>A.G.</given-names></name></person-group><article-title>Clindamycin clearance during Cytosorb<sup>&#174;</sup> hemoadsorption: A case report and pharmacokinetic study</article-title><source>Int. J. Artif. Organs</source><year>2019</year><volume>42</volume><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1177/0391398819831303</pub-id><pub-id pub-id-type="pmid">30819024</pub-id></element-citation></ref><ref id="B307-antibiotics-13-00801"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brandenburger</surname><given-names>T.</given-names></name><name name-style="western"><surname>MacKenzie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kindgen-Milles</surname><given-names>D.</given-names></name></person-group><article-title>Elimination of glycopeptide antibiotics by cytokine hemoadsorption in patients with septic shock: A study of three cases</article-title><source>Int. J. Artif. Organs</source><year>2020</year><volume>43</volume><fpage>753</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1177/0391398820917151</pub-id><pub-id pub-id-type="pmid">32342769</pub-id></element-citation></ref><ref id="B308-antibiotics-13-00801"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#246;hler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schwier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kirchner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Winde</surname><given-names>G.</given-names></name><name name-style="western"><surname>Henzler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eickmeyer</surname><given-names>C.</given-names></name></person-group><article-title>Hemoadsorption with CytoSorb<sup>&#174;</sup> and the early course of linezolid plasma concentration during septic shock</article-title><source>J. Artif. Organs</source><year>2021</year><volume>25</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s10047-021-01274-4</pub-id><pub-id pub-id-type="pmid">34047868</pub-id><pub-id pub-id-type="pmcid">PMC8866295</pub-id></element-citation></ref><ref id="B309-antibiotics-13-00801"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liebchen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weinelt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C.</given-names></name><collab>the CytoMero Collaboration Team</collab><name name-style="western"><surname>Michelet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>I.</given-names></name><name name-style="western"><surname>Paal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M.</given-names></name><etal/></person-group><article-title>No clinically relevant removal of meropenem by cytokine adsorber CytoSorb<sup>&#174;</sup> in critically ill patients with sepsis or septic shock</article-title><source>Intensive Care Med.</source><year>2021</year><volume>47</volume><fpage>1332</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1007/s00134-021-06487-y</pub-id><pub-id pub-id-type="pmid">34519848</pub-id><pub-id pub-id-type="pmcid">PMC8550492</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antibiotics-13-00801-f001" orientation="portrait"><label>Figure 1</label><caption><p>Search results. PRISMA Flow Diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antibiotics-13-00801-g001.jpg"/></fig><fig position="float" id="antibiotics-13-00801-f002" orientation="portrait"><label>Figure 2</label><caption><p>Number of studies with the ten most relevant risk factors. (<bold>a</bold>) For risk factors. (<bold>b</bold>) For antibiotics.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antibiotics-13-00801-g002.jpg"/></fig><fig position="float" id="antibiotics-13-00801-f003" orientation="portrait"><label>Figure 3</label><caption><p>Details of variables included renal function, hepatic function, weight, and renal replacement therapy as risk factors. AKI: Acute kidney injury, ARC: Augmented renal clearance, BMI: body mass index, BSA: body surface area, CRRT: continuous renal replacement therapy, SLED: sustained low-efficiency dialysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antibiotics-13-00801-g003.jpg"/></fig><fig position="float" id="antibiotics-13-00801-f004" orientation="portrait"><label>Figure 4</label><caption><p>Risk factors with different relevance versus those analyzed, represented on two different scales. The size of the ball indicates the number of patients analyzed. ECMO: Extracorporeal Membrane Oxygenation; Hb: Hemoglobin; Ht Hematocrit.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antibiotics-13-00801-g004.jpg"/></fig><table-wrap position="float" id="antibiotics-13-00801-t001" orientation="portrait"><object-id pub-id-type="pii">antibiotics-13-00801-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of the studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#B3D0EB" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#B3D0EB" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#B3D0EB" rowspan="1" colspan="1">Number of Studies</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#B3D0EB" rowspan="1" colspan="1">Number of Patients</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>Number of Centers</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Unicentric</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">222</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">11,342</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Multicentric</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">34</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">10,157</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Study Design</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective observational</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21,089</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">411</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>Outcome type</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Exposure</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">113</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">15,702</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">PKPOP</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">101</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">4628</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">PK</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">42</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">1170</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Type of analysis</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subgroup</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4827</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subgroup and PKPOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2093</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk factor, no PKPOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,045</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk factor and PKPOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2535</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>Distribution of studies by area</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Europe</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">125</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">7036</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">North America</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">39</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">9303</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">East Asia</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">39</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">2707</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Oceania</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">21</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">700</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">South Asia</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">9</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">335</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">South America</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">689</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Africa</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">5</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">187</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">More than one area</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">5</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">493</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Middle East</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">43</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Publication year</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1988&#8211;1996 (9 years)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">117</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1997&#8211;2005 (9 years)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">445</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2006&#8211;2014 (9 years)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1997</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#8211;2024 (9.2 years)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">192</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18,941</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>Antibiotic group evaluated</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">More than two antibiotic groups</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">6</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">256</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Aminoglycosides</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">20</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">1767</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Antituberculous</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Beta lactams</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">137</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">7395</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Daptomycin</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">4</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">101</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Linezolid</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">23</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">643</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Polimyxins</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">7</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">207</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Quinolones</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">11</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">258</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Teicoplanin</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">7</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">416</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Tigecycline</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">4</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">89</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">Vancomycin</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">42</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">10,602</td></tr></tbody></table><table-wrap-foot><fn><p>PK: Refers to studies that have investigated how risk factors affect pharmacokinetic variables; PKPOP: Refers to studies that have investigated the impact of risk factors as covariates in a population model.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="antibiotics-13-00801-t002" orientation="portrait"><object-id pub-id-type="pii">antibiotics-13-00801-t002_Table 2</object-id><label>Table 2</label><caption><p>Number and Percentage of Studies that Concluded a Risk Factor as a Determinant, and the number and percentage that Analyzed Each Risk factor, Classified by Antibiotic Group and Outcome.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#B3D0EB" rowspan="1" colspan="1">
</th><th colspan="11" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#B3D0EB" rowspan="1">Antibiotic Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#B3D0EB" rowspan="1" colspan="1">Total</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Risk Factor/Primary Outcome</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Amino-Glycosides</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">B-Lactams <sup>2</sup></th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">B-Lactams Vancomycin</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Daptomycin</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Linezolid <sup>2</sup></th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Polymyxins</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Quinolone</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Teicoplanin</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Tigecycline</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Vancomycin</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Other <sup>1</sup></th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Number of Studies</th></tr></thead><tbody><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/10 (10.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">9/80 (11.3)</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/11 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/4 (25.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/9 (22.2)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/4 (25.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3(0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/16 (18.8)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>17/139 (12.2)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">1/5 (20.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/20 (15.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2(50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/6 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">8/41 (19.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/60 (10.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/10 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/7 (14.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/3(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/10 (20.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/98 (9.2)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/8 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>4/68 (5.9)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/8 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/6 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/15 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>6/115 (5.2)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/15 (6.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/6 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3/31 (9.7)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/53 (5.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/8 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/3 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/9 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/84 (3.6)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Weight</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>5/7 (71.4)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>30/88 (34.1)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>6/12 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/6 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>4/8 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/3 (66.7)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>8/17 (47.1)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>57/146 (39.0)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">6/22 (27.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/4 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3/5 (60.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">14/40 (35.0)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/5 (80.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/66 (36.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/10 (50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/6 (50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3 (66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/12 (41.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43/106 (40.6)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Renal function</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>8/11 (72.7)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>74/98 (75.5)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/2 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>8/13 (61.5)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/5 (60.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>6/8 (75.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/4 (75.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>18/24 (75.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/2 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>125/170 (73.5)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">4/5 (80.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">24/30 (80.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/3 (66.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/3 (66.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">10/12 (83.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">48/61 (78.7)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/6 (66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50/68 (73.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/11 (63.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/5 (80.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3 (66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/12 (66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77/109 (70.6)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Renal replacement</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/7 (42.9)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>22/50 (44.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/3 (66.7)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/3 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>5/14 (35.7)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/2 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/5 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/5 (60.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>13/17 (76.5)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/3 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>57/110 (51.8)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">1/4 (25.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">9/21 (42.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/4 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">7/9 (77.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">26/45 (57.8)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3 (66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/29 (44.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/2 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/10 (30.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/8 (75.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/2 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31/65 (47.7)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Protein or albumin</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/4 (25.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>10/49 (20.4)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/4 (25.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/4 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>15/70 (21.4)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/10 (10.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">4/17 (23.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/39 (23.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/53 (20.8)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>APACHE or SAPS</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/6 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>5/46 (10.9)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/6 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/11 (9.1)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>11/81 (13.6)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">2/4 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/14 (21.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/6 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">8/30 (26.7)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/32 (6.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/51 (5.9)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>SOFA score</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/5 (40.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>5/46 (10.9)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/5 (20.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/10 (10.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>11/74 (14.9)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">2/3 (66.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">4/13 (30.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">8/25 (32.0)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/33 (3.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/5 (20.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/6 (16.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/49 (6.1)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Hepatic function</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/23 (4.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>5/8 (62.5)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/6 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>11/49 (22.4)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/11 (27.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/20 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/8 (62.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/4 (50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/38 (21.1)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Sepsis/shock</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/6 (16.7)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>7/39 (17.9)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/11 (18.2)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>12/63 (19.0)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/13 (23.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2/7 (28.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">7/27 (25.9)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/26 (15.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/36 (13.9)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Admission</bold>
<break/>
<bold>Diagnosis</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/17 (5.9)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/7 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/30 (6.7)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/6 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/15 (6.7)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/11 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/3 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/15 (6.7)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Trauma</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/5 (60.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>5/9 (55.6)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2/6 (33.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/3 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/3 (100)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Burn</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/2 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>6/9 (66.7)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>8/13 (61.5)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">5/6 (83.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">6/8 (75.0)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/5 (40.0)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>ECMO</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>6/14 (42.9)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/2 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/2 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>11/25 (44.0)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/5 (20.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">5/11 (45.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/9 (55.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/14 (42.9)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>Mechanical</bold>
<break/>
<bold>ventilation</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/4 (0)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/14 (7.1)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/5 (20.0)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/24 (12.5)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/4 (25.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/11 (9.1)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/10 (10.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/13 (15.4)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>pH parameters</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>4/7 (57.1)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/5 (60.0)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Acute reactants</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/19 (15.8)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>4/28 (14.3)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/4 (25.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2/8 (25.0)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/15 (13.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/20 (10.0)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Hemoglobin/hematocrit</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/7 (14.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/14 (14.3)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/3 (0)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/6 (16.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/11 (18.2)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Fluid balance</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/4 (25.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/15 (13.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/26 (11.5)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/3 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/9 (11.1)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/12 (8.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/17 (11.8)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Comorbidities</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/4 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/14 (21.4)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/6 (16.7)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>4/29 (13.8)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/6 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/15 (13.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/8 (25.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/4 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/14 (14.3)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Comedication</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/10 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/1 (100)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/2 (50.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>2/20 (10.0)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/12 (8.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/3 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/8 (12.5)</td></tr><tr><td align="left" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>Site of infection</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/3 (33.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>3/21 (14.3)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>1/4 (25.0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/2 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/1 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0/3 (0)</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" valign="middle" style="background:#E8EEF8" rowspan="1" colspan="1">
<bold>5/37 (13.5)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exposure</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/9 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">4/17 (23.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/PKPOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/12 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/20 (5.0)</td></tr></tbody></table><table-wrap-foot><fn><p>ECMO: Extracorporeal membrane oxygenation. PK: Studies that have investigated how risk factors affect pharmacokinetic variables; PKPOP: Studies that have investigated the impact of risk factors as covariates in a population model. <sup>1</sup> Other includes studies with more than two groups of antibiotics and one study on antitubercular agents. <sup>2</sup> A study that evaluated linezolid and beta-lactams together, this has been counted as two studies.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>